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Abstract 
Background : Sedentary lifestyle along with easy access to fast foods have resulted in a 
global epidemic of diabetes with a prediction that it will rise from the current estimate of 190 
million to 324 million in 2025. WHO predicts that 170% increase of diabetes will be in the 
developing countries. Type 2 diabetes (T2DM) has become one of the major causes of 
premature illness and death and cardiovascular disease (CVD) will be responsible for up to 
80% of these deaths. So it seems that at the moment we are faced with the twin pandemic of 
T2DM and CVD and the brunt of this would be borne by the developing countries. The 
clustering of central obesity, dyslipidaemia, hypertension, and hyperglycaemia known as 
metabolic syndrome has been associated with a 2-3 fold increase in T2DM and CVD. It is 
recognized that the features of the metabolic syndrome can be present 10 years preceding 
T2DM and CVD. The prevalence rates of metabolic syndrome appear varied using the WHO, 
EGIR, AACE, ATP III and IDF definitions. Therefore it is needed to study the suitability of 
metabolic syndrome definitions in this population.  
Objective: To estimate the prevalence of metabolic syndrome in adults aged 25 years and 
above from an urban population of Karachi.  
Methods: The survey was conducted from July to December 2004 by generating a 
computerized random sample of 500 households from houses in Lyari Town using a 
Geographical Imaging System (GIS). The survey activities were divided into two phases—the 
household interview and blood sample collection. Field work entailed visits to the selected 
household by a field team (medical students and health worker), introduction to the purpose 
of the research study, consent, interviews and physical measurements. In the 532 
households visited 867 adults > 25 years old consented to take part in the survey out of 
which 363 gave blood samples. 
Results: Prevalence of Diabetes was 9.4% while 5.6% had impaired fasting glucose 
(Abnormal glucose tolerance 15%). Prevalence of metabolic syndrome was found to be 49% 
by modified ATP III, 34.8% by IDF, 16.9% by AACE, 15.2% by EGIR and 7.4% by WHO 
definition. Insulin resistance defined by 75th percentile of HOMA-IR was measured as 1.94. 
Conclusion: Inclusion of modified waist circumference and BMI cutoffs may help to predict 
metabolic syndrome more precisely as incorporated in modified ATP III and IDF definition. 
The rising prevalence of obesity and metabolic syndrome has received increased attention in 
recent years as both place individuals at risk for T2DM and CVD. Thus epidemiological and 
intervention trial studies which support lifestyle changes as the main modifiable risk factor in 
the treatment of individual components of the metabolic syndrome can then be initiated.  
Key Words: Prevalence, Metabolic Syndrome, IDF Definition, Diabetes, Pakistan, WHO, 
Modified ATP III 
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1.1 Background - Diabetes Mellitus and CVD  
 
Changes in work patterns from heavy labour to sedentary, the increase in 
computerization and mechanization, and improved transport are just a few of the 
changes that have made an impact on human health (1). These sedentary changes 
along with easy access to fast foods and empty calories have resulted in escalating 
rates of both obesity and type 2 diabetes globally (2,3). Paradoxically, part of the 
problem relates to the achievements in public health during the 20th century, with 
people living longer owing to elimination of many of the communicable diseases (4). 
Non-communicable diseases (NCD) such as diabetes and cardiovascular disease 
(CVD) have now become the main public health challenge for the 21st century, as a 
result of their impact on personal and national health system and the premature 
morbidity and mortality associated with the NCDs (1,5). 
 
1.1.1 Diabetes Mellitus 
 
Diabetes mellitus is a metabolic disorder with both genetic and lifestyle etiologies that 
results in abnormal glucose control. It is a chronic disease caused by inherited and/or 
acquired deficiency in production of insulin by the pancreas, or by the ineffectiveness 
of the insulin produced. An acquired deficiency may be triggered by life style factors. 
However a deficiency of insulin results in increased concentrations of glucose in the 
blood, which in turn damages many of the body's systems. Genetics has an 
influential role on the epidemiology of the disease.  
 
1.1.2 Global Burden of Diabetes  
 
The global figure of people with diabetes is set to rise from the current estimate of 
190 million to 324 million in 2025 (6,7). WHO predicts 170% increase in the number 
of people with diabetes for the developing countries (6).The greatest increase 
is projected in India (195%) (6).  
The past two decades have seen an explosive increase in the number of people 
diagnosed with diabetes worldwide and 75% of these will be from the developing 
countries (6). This trend of increasing prevalence of diabetes and obesity has already 
imposed a huge burden on health-care systems and this will unfortunately continue to 
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increase in the future (1,8). The magnitude of the problem has caught the public 
health community by surprise. 
Each year, 3.2 million people around the world die from complications associated 
with diabetes. In countries with a high diabetes incidence, such as those in the Pacific 
and the Middle East, as many as one in four deaths in adults aged between 35 and 
64 years is due to the disease. Type 2 diabetes has become one of the major causes 
of premature illness and death, mainly through the increased risk of CVD which is 
responsible for up to 80 per cent of these deaths (7,9). 
Type 2 diabetes (and its associated hyperglycaemia or dysglycaemia) is a 
manifestation of a much broader underlying disorder – the metabolic syndrome 
(3,10). This includes a cluster of CVD risk factors that, in addition to glucose 
intolerance (that is, IGT or diabetes), includes hyperinsulinaemia, dyslipidaemia, 
hypertension, visceral obesity, hypercoagulability and microalbuminuria.  
 
1.1.3 Ischemic Heart Disease 
 
Ischemic Heart Disease (IHD) - also known as Coronary Heart Disease (CHD) - 
refers to a group of closely related syndromes caused by an imbalance between 
myocardial oxygen demand and blood supply (11,12). The most common cause of 
IHD is a reduction in coronary arterial blood supply due to atherosclerosis of the 
coronary arteries (12). 
 
1.1.4 Global Burden of Cardiovascular Disease 
 
It is estimated that 17 million people died of cardiovascular diseases (CVD) during 
2001(13).  The most common reported types of CVD were IHD, hypertension (HTN) 
and rheumatic heart disease (13). The World Health Report 1999 estimates that 31% 
of all deaths in 1998 as well as 10% of the total disease related burden in terms of 
Disability Adjusted Life Years loss (DALYs) were attributable to CVD (14). 
The metabolic syndrome has been associated with a 2–3 fold risk of cardiovascular 
disease and more important than this is the clustering of the heart attack risk factors 
in this syndrome: diabetes and raised fasting plasma glucose, abdominal obesity, 
high cholesterol and high blood pressure (15-17). 
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Developed Countries 
 
The rates of CVD are comparable or higher among persons of African origin than 
those found in whites in the US (18). In Western Europe, CVD is responsible for 
about one third of all deaths (12,18). Eastern European countries such as the 
Ukraine, the Russian Federation, Hungary, and the Czech Republic have among the 
highest CVD rates in the world which is still rising. This is in marked contrast to the 
more economically stable Western European countries where declines in CVD 
mortality rates have been observed over the past 30 years (19). 
 
Developing Countries 
 
Globally low and middle income countries account for 78% of all CVD-attributable 
deaths and 86% of all CVD-attributable DALY loss (14). As far back as 1990, 
developing countries accounted for 63% of all CVD deaths and 74% of CVD related 
DALY loss (20). It has been estimated that 5.3 million deaths attributable to CVD 
occurred in developed countries in 1990, whereas the corresponding figure for 
developing countries ranged between 8 to 9 million [i.e., a relative excess of 70%] 
(21).This CVD burden afflicts both men and women, with CVD accounting for 34% of 
all deaths in women and 28% in men during 1998 (14). The high burden of CVD in 
developing countries is attributable both to the increased incidence of these disorders 
as well as the relatively early age at which they manifest (13,22-26). For example, 
47% of the deaths attributable to CVD in developing countries in 1990 occurred 
below the age of 70 years, in contrast to 23% of such deaths in high income industrial 
countries (27). The contribution of developing countries to the global burden of CVD 
in terms of disability adjusted years of life lost was three times higher than that of 
developed countries (28). 
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  Figure 1: Metabolic Syndrome - Clustering of CVD Risk Factors 
 
 
1.2 Metabolic Syndrome (Diabetes and CVD Epidemic)  
 
Over the last 20 years, the prevalence of the metabolic syndrome has steadily 
increased in all populations worldwide making this one of the major global public-
health challenges (15). The ultimate importance of the metabolic syndrome is that it 
helps to identify individuals at high risk of developing both type 2 diabetes and 
cardiovascular disease (CVD).  
It is estimated that around 20-25 per cent of the world’s adult population have the 
metabolic syndrome and they are twice as likely to die from and three times as likely 
to have a heart attack or stroke compared with people without the syndrome (29). 
In addition, people with metabolic syndrome have a fivefold greater risk of developing 
type 2 diabetes (30). They would add to the 230 million people worldwide who 
already have diabetes, one of the most common chronic diseases worldwide and the 
fourth or fifth leading cause of death in the developed world (31). The clustering of 
cardiovascular disease (CVD) risk factors that typifies the metabolic syndrome is now 
considered to be the driving force for a new CVD epidemic.  
This ‘clustering’ of metabolic abnormalities that occur in an individual appear to 
confer a substantial additional cardiovascular risk over and above the sum of the risk 
associated with each abnormality (32,33). Thus it appears that the more components 
of the metabolic syndrome that are evident, the higher is the cardiovascular mortality 
rate (34). And at the moment we are faced with the twin pandemics of T2DM and 
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cardiovascular disease and that the brunt of this would be borne by many poor and 
developing countries (6, 28). 
 
1.2.1 History of the Metabolic Syndrome   
 
One of the earliest descriptions of the metabolic syndrome was by Kylin in 1923 when 
he described the involvement of hypertension, hyperglycemia, and high uric acid 
levels (35). In the late 1940s and early 1950s, Jean Vague presented a series of 
reports on the sexual differentiation of obesity and its consequences. Vague later 
identified the masculine form of abdominal obesity and described the relationship 
between abdominal obesity, fat distribution and their association with diabetes and 
other chronic disorders (36,37). In 1987 he presented a updated review of what he 
termed as “diabetogenic obesity” in a lecture at the Fifth International Congress on 
Obesity (38). In the early 1960s, Avogaro and Crepaldi described a syndrome, which 
involved hypertension, hyperglycemia, and obesity (39). Camus was another early 
observer of these associations and in 1966 he identified the “trisyndrome 
métabolique” to include goutte, diabéte, and hyperlipémie (40). Later in the late 
1970s Pyorala also showed strong links between glucose intolerance, 
hyperinsulinemia, and coronary heart disease in a study of two sets of the Finnish 
population (41). In the 1980s, Modan et al. also described this  link between obesity, 
hypertension, and cardiovascular disease (CVD) (42). 
 
In 1988 Reaven described “a cluster of risk factors predisposing a person towards 
diabetes and cardiovascular disease” naming this as Syndrome X. This was the first 
time that the insulin resistant state was implicated as being central to this collection of 
cluster of risk factors of Syndrome X (43).  
 
After Reaven put forward his concept of Syndrome X, there were many attempts to 
introduce the concept of risk factor clustering for cardiovascular disease and type 2 
diabetes mellitus (T2DM) into the general clinical arena with different names such as  
“deadly quartet”  and “insulin resistance syndrome” etc but for some time now this 
has come to be referred as the “Metabolic Syndrome”. 
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1.2.2 Evolution of Metabolic Syndrome Definition - towards a global consensus  
 
In 1998 the World Health Organization (WHO) published the definition of metabolic 
syndrome closely followed in the next year by European Group for the Study of 
Insulin Resistance (EGIR) (44,45). In 2001 the National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III) came out with their definition, 
followed in 2003 by the American Association of Clinical Endocrinologists (AACE) 
(46,47), and most recently that of the International Diabetes Federation defined in 
2005 (48). In 2005, National Heart, Lung, and Blood Institute; American Heart 
Association came up with the criteria which slightly modified the ATP III definition 
(49). 
Thus the first attempt to define this syndrome was in 1998 by a WHO diabetes group 
which had insulin resistance, impaired glucose tolerance or diabetes, as essential 
components, together with at least two other components (Table 1).  
In 1999, the European Group for Study of Insulin Resistance (EGIR) reverted to the 
term insulin resistance syndrome (45). Insulin resistance; a primary requirement was 
defined as plasma insulin levels in the upper quartile of the population. 
Predetermined cut points for the other criteria were used (Table 1). EGIR focused 
more on abdominal obesity than did WHO, but in contrast to WHO, EGIR excluded 
patients with type 2 diabetes mellitus from their definition.  
In 2001, the National Cholesterol Education Program, Adult Treatment Panel III 
(NCEP, ATP III) introduced an alternative clinical criteria for defining the metabolic 
syndrome, with the aim of identifying people at long-term risk for ischemic heart 
disease (46). While insulin resistance was recognized as been important, the  
requirement was excluded from the definition. The ATP III criteria did not mandate 
the requirement of any single factor for diagnosis, but instead made the presence of 
three of five factors as the basis for establishing the diagnosis; these factors being 
abdominal obesity, elevated triglycerides, reduced HDL-C, elevated blood pressure, 
and elevated fasting glucose (IFG or type 2 diabetes mellitus) (Table 1).  
In 2003, the American Association of Clinical Endocrinologists brought the focus back 
on insulin resistance as the primary aetiology underlying the primary metabolic risk 
factors (47). Calling it the insulin resistance syndrome, the definition included major 
criteria, which were IGT, elevated triglycerides, reduced HDL-C, elevated blood 
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pressure, and obesity. Other factors needed to form clinical judgment were a family 
history of  CVD or type 2 diabetes mellitus, polycystic ovary syndrome, and 
hyperuricemia. They did not specify any absolute requirement or even the number of 
factors, which had to be present to merit the diagnosis of the metabolic syndrome 
rather leaving the diagnosis to the clinician's judgment (Table 1).  
In 2005, the International Diabetes Foundation (IDF) published their criteria and tried 
to keep the requirements for the diagnosis of the metabolic syndrome as clinically 
simple and widely usable as possible (48). The IDF clinical definition made the 
presence of abdominal obesity obligatory for diagnosis. Once this essential condition 
was present, at least two additional factors out of four were necessary for the 
diagnosis. The IDF definition recognized and emphasized ethnic differences in the 
correlation between abdominal obesity and other metabolic syndrome risk factors. 
The criteria of abdominal obesity were specified by nationality or ethnicity based on 
best available population estimates. (Table 1).  
Also in 2005, the AHA/NHLBI statement, kept to the basic ATP III criteria except for 
few minor changes (46,49). The AHA/NHLBI diagnostic criteria for metabolic 
syndrome [49], popularly known as the modified ATP III definition, has no mandatory 
criteria which had to be present. One major change was the reduction from 110 to 
100 mg/dl for the diagnosis of IFG; this adjustment corresponded to the recently 
modified American Diabetes Association (ADA) criteria for IFG (Table 1).  
Different ethnic backgrounds, diets, levels of physical activity, population age and sex 
structure and levels of nutrition, all influence the prevalence of the metabolic 
syndrome making it even more difficult to identify a predictive definition. What we 
know is that this syndrome predicts high risk of cardiovascular disease and diabetes 
(50).  
Unfortunately the concept and definition of the metabolic syndrome are still subject to 
debate (51,52), including the applicability of a single definition to people of different 
ethnic origin (15). Whether any current definition of the metabolic syndrome is a 
better predictor than the others as a marker for increased risk of cardiovascular 
disease and diabetes is unresolved.  
One has to understand that the metabolic syndrome definition is still evolving and 
would constantly do so as more and more data comes in. Furthermore, there is no 
reason to expect that there should be consensus on the definitions as each definition 
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was developed to correct the previous definitions, thus it would be unlikely that they 
would basically be similar.  
At the same time, if one sees the timeline of the various definitions, it becomes clear 
that we are moving towards some sort of a consensus on what defines the metabolic 
syndrome as shown (Table 1).  
Table 1. Previous criteria proposed for the diagnosis of metabolic syndrome  
Clinical 
measure  
 
WHO (1998)  
 
EGIR  ATP III (2001)  AACE (2003)  
 
IDF (2005)  
Insulin 
resistance 
IGT, IFG, T2DM, 
or lowered insulin 
sensitivity plus any 
2 of the following 
Plasma insulin 
>75th percentile 
plus any 2 of the 
following 
None, but any 3 
of the following 5 
features 
IGT or IFG plus 
any of the 
following based 
on clinical 
judgment 
None 
Body 
weight 
Men: waist-to-hip 
ratio >0.90; women: 
waist-to-hip ratio 
>0.85 and/or BMI 
>30 kg/m2 
WC ≥94 cm in 
men or ≥80 cm 
in women 
WC ≥102 cm in 
men or ≥88 cm in 
women 
BMI ≥25 kg/m2 
Increased WC 
(population 
specific) plus 
any 2 of the 
following 
Lipid 
TG ≥150 mg/dl (1.7 
mmol/l) and/or  
 
TG ≥150 mg/dl 
(1.7 mmol/l) 
and/or  
TG ≥150 mg/dl 
(1.7 mmol/l) 
TG ≥150 mg/dl 
(1.7 mmol/l)and  
TG ≥150 mg/dl 
(1.7 mmol/l) or 
on TG Rx 
 
HDL-C <35 mg/dl 
(0.90 mmol/l) in 
men or <39 mg/dl 
(1.01 mmol/l) in 
women 
HDL-C 
<39 mg/dl (1.01 
mmol/l) in men 
or women 
HDL-C 
<40 mg/dl (1.03 
mmol/l) in men or 
<50 mg/dl (1.29 
mmol/l) in 
women 
HDL-C 
<40 mg/dl (1.03 
mmol/l) in men or 
<50 mg/dl (1.29 
mmol/l) in 
women 
HDL-C 
<40 mg/dl 
(1.03 mmol/l) 
in men or 
<50 mg/dl 
(1.29 mmol/l) 
in women or on 
HDL-C Rx 
Blood 
pressure ≥140/90 mmHg 
≥140/90 mmHg 
or on 
hypertension Rx 
≥130/85 mmHg ≥130/85 mmHg 
≥130 mmHg 
systolic or 
≥85 mmHg 
diastolic or on 
hypertension 
Rx 
Glucose IGT, IFG, or T2DM IGT or IFG (but not diabetes) 
>110 mg/dl (6.1 
mmol/l) (includes 
diabetes)a 
IGT or IFG (but 
not diabetes) 
≥100 mg/dl 
(5.6 mmol/l) 
(includes 
diabetes) 
Other Microalbuminuria   Other features of insulin resistanceb  
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a The 2001 definition identified fasting plasma glucose of ≥110 mg/dl (6.1 mmol/l) as 
elevated. This was modified in 2004 to be ≥100 mg/dl (5.6 mmol/l), in accordance with the 
American Diabetes Association's updated definition of IFG. 
b Includes family history of type 2 diabetes mellitus, polycystic ovary syndrome, sedentary 
lifestyle, advancing age, and ethnic groups susceptible to type 2 diabetes mellitus.  
It is quite possible that further changes may be made to the definitions as more data 
comes in from all over the world. After all, it is essential that we take a global view of 
the risks involved and the criteria may need to be changed in order to be inclusive 
and take into consideration the ethno-heterogeneity of the so called global village! 
This is definitely not a case where one size fits all, but one that requires needs to be 
“made to fit” so that it can have global clinical relevance.  
 
An example of ethno-heterogeneity was  the case of Asian Indians, who have been 
found to be at greater risk to obesity and insulin resistance than Caucasians, and 
researchers felt that the BMI cut-off should be decreased to <23 kg/m2 rather than 
<25 kg/m2 which was used as normal. This was accepted and different BMI cut –off 
have been defined for Asians. If that is the case, it might also appear that the 
uniformity and consensus in terms of the definition of metabolic syndrome is further 
questioned. But, it should rather appear that the consensus lies in appreciating the 
lack of uniformity of a universal definition and being sensitive to ethno-heterogeneity 
of risk factors. 
Reaven stated in a recent report that it appears that studies demonstrating the 
relationship between increased abdominal obesity and adverse clinical 
consequences have relied on at least 14 different methods to quantify waist 
circumference (WC) and even the 4 most commonly used approaches yielded quite 
different absolute values for WC (53,54). This issue is further highlighted by a recent 
report from the WHO expressing concern that since the untoward effects of obesity 
will vary in different ethnic groups, it will be necessary to develop ethnicity-specific 
values to identify overweight/obese individuals at greatest risk (55).  
The good news is that some of these criticisms have already been clarified by the 
updated NCEP and the IDF definitions which are the latest versions of the definition. 
It appears that we are moving towards a consensus definition of sorts as shown in 
table 2 (48,49).  
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Table 2. IDF and AHA/NHLBI 
Comparison of diagnostic criteria for the metabolic syndrome from the International Diabetes 
Federation (IDF) and American Heart Association (AHA)/National Heart, Lung, and Blood 
Institute (NHLBI)  
IDF clinical criteria for metabolic syndrome  AHA/NHLBI diagnostic criteria for metabolic syndrome  
Measure (central 
obesity plus any two 
of five other criteria 
constitute a diagnosis 
of metabolic 
syndrome)  
 
Categorical cut points  
Measure (any three 
of the five criteria 
below constitute a 
diagnosis of 
metabolic syndrome) 
Categorical cut points  
Central obesity 
Waist circumference 
ethnicity specific  
For South Asians: 
≥ 90 cm in men, 
≥ 80 cm in women 
 
Elevated waist 
circumference 
General U.S. population: 
≥102 cm (≥40 in.) in men, 
≥88 cm (≥35 in.) in women; 
lower cut points for insulin-
resistant individuals or ethnic 
groups (based on clinical 
judgment) 
Raised triglycerides 
>150 mg/dl (1.7 mmol/l) 
or on specific treatment 
for this lipid disorder 
Elevated triglycerides 
≥150 mg/dl (1.7 mmol/l) or on 
drug treatment for elevated 
triglycerides 
Reduced HDL 
cholesterol 
<40 mg/dl (1.03 mmol/l) 
in men, <50 mg/dl 
(1.29 mmol/l) in women 
or on specific treatment 
for this lipid abnormality 
Reduced HDL 
cholesterol 
<40 mg/dl (1.03 mmol/l) in 
men, <50 mg/dl (1.29 mmol/l) 
in women 
Raised blood pressure 
≥130 mmHg systolic 
blood pressure or 
≥85 mmHg diastolic blood 
pressure or on treatment 
for previously diagnosed 
hypertension 
Elevated blood 
pressure 
≥130 mmHg systolic blood 
pressure or ≥85 mmHg 
diastolic blood pressure or on 
drug treatment for hypertension
Raised fasting glucose 
Fasting plasma glucose 
≥100 mg/dl (5.6 mmol/l) 
or previously diagnosed 
type 2 diabetes 
  
 
Studies have shown that the presence of the metabolic syndrome confers a two-fold 
increase in the risk for major CVD events and a five-fold increase in the life-time risk 
for T2DM [56 - 58). Although the precise increase in the risk may vary depending on 
the population being studied, from a clinical viewpoint the presence of the metabolic 
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syndrome identifies a person at higher lifetime risk for major CVD events and/or 
T2DM (57). 
One has to realize that almost 200 million people globally have diabetes and 80% of 
these will die from cardiovascular disease. Thus it seems that the reason for the IDF 
for coming out with these clinically simple to use guidelines was the firm belief that 
we are in the midst of a twin pandemic of T2DM and cardiovascular disease which 
seems to be driven by the metabolic syndrome and the presence of the associated 
correlates in the metabolic syndrome confers a manifold increase in the risk for T2DM 
and CVD (56). Taking a global view, it becomes not only a medical, but also a socio-
economic need to take all steps to try and prevent the ravages which can be caused 
by T2DM and CVD (2). 
The risk factors underlying cardiovascular disease can be divided into (59); 
(a) Major risk factors, such as cigarette smoking, elevated LDL-C and VLDL-C, low 
HDL-C, elevated blood pressure, diabetes, metabolic syndrome and advanced 
atherosclerotic burden.  
(b) Emerging risk factors being, prothrombotic stage, proinflammatory state, insulin 
resistance  
(c) Underlying risk factors being atherogenic diet, obesity, physical inactivity & family 
history.  
1.2.3 Epidemiology of the Metabolic Syndrome  
The widespread use of the different metabolic syndrome definitions has resulted in a 
large number of publications describing varied levels of prevalence of the disease.  
The NCEP criteria have been used in a broad spectrum of cases; HIV subjects, 
American indigenous population and in representative surveys of many countries 
(60–64).  The prevalence of the NCEP-metabolic syndrome in the U.S. was initially 
reported in the Third National Health and Nutrition Examination Survey (NHANES III, 
1988–1994). The age-adjusted prevalence was 23.7% (62). The contribution of the 
various components was different among ethnic groups. Low HDL cholesterol, 
hyperglycemia and hyper-triglyceridemia made a significantly greater contribution in 
Mexican-Americans compared to arterial hypertension which was more prevalent in 
African-Americans. 
The prevalence of the NCEP-metabolic syndrome was updated in the U.S. using the 
NHANES 1999–2000. The age-adjusted prevalence increased from 24.1 to 27% (63). 
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Remarkably, an increased prevalence was observed mainly in women younger than 
40 years of age. These results are a worrisome indicator of future trends in diabetes 
and CVD in the U.S as well as showing where trends are going globally. 
The WHO criteria have been used mainly in European cohorts (61). The prevalence 
of the WHO-metabolic syndrome in non-diabetic subjects varied between 7 and 36% 
for men 40–55 years and between 5 and 22% for women of the same age group. The 
same trends were observed if patients with or without diabetes were included in the 
analysis.  
Analyses of data from large, prospective studies suggest that the metabolic 
syndrome itself is an important risk factor for CHD and type 2 DM, and that the 
metabolic syndrome increases total mortality and cardiovascular mortality (58). 
The Botnia study followed individuals from families with type 2 DM in Finland and 
Sweden (65). According to an analysis of 4483 subjects aged 35–70 years, the 
prevalence of the metabolic syndrome according to WHO criteria increased in a 
stepwise fashion with worsening glucose tolerance. Over a median follow-up period 
of 7 years, the presence of the metabolic syndrome tripled the risk of CHD and 
doubled the risk of myocardial infarction and stroke. The risk of cardiovascular 
mortality was 80% greater in subjects with the metabolic syndrome than in those 
without, and the risk of all-cause mortality was also significantly greater.  
A12-year follow-up data was examined from a Finnish study of 2682 middle-aged 
men who did not have cardiovascular disease or diabetes at baseline (66). Death 
from CHD was 2.9–4.2 times more likely among men with the metabolic syndrome 
than among those without, depending on how the syndrome was defined. In addition, 
the presence of the metabolic syndrome doubled the risk of death from any cause.  
Associations between the metabolic syndrome, CHD, and diabetes have also been 
established by an analysis of the cross-sectional NHANES III data on adults aged 
>50 years (67). As in the Botnia study, a stepwise increase in the prevalence of the 
metabolic syndrome was observed with worsening glucose tolerance, and 86% of 
people with diabetes had the metabolic syndrome (65). The prevalence of CHD was 
19% in people with both the metabolic syndrome and diabetes versus 9% in those 
with neither and 7.5% in the small percentage of the study population that had 
diabetes but not the metabolic syndrome. These results suggest that for most 
diabetic patients, cardiovascular risk is related not to diabetes itself but to the 
concomitant presence of the metabolic syndrome (68). 
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Currently available definitions are extremely valuable tools for studying the disease. 
However the current definitions include, in affected and non-affected subjects a 
heterogeneous group of cases with a broad range of relative risks for future 
complications, which need to be refined. The refinement of the definitions will allow 
the correct identification of cases and controls for genetic studies, the method most 
likely to provide the gold standard for the diagnosis of the syndrome (69).  
Finally, the metabolic syndrome should be considered as a prime target for 
preventive medicine. Clearly, the emerging global epidemic of metabolic and vascular 
disease has significant implications for the development of population health 
promotion strategies. Lifestyle modifications and weight loss programs are a key part 
of the program because weight loss reduces the incidence of type 2 diabetes and a 
large percent of the affected subjects had excess body weight (70). However, long-
term efficacy of the weight loss programs is far from ideal. Unless preventive 
programs are properly designed and implemented, we will continue to treat the 
majority of the cases when they have reached the steeper extreme of the road: when 
many have already developed the complications of the metabolic syndrome. 
1.2.4 Metabolic Syndrome in South Asians 
In the future 70% of new incident cases of diabetes will be in the developing countries 
(71). Among the ten leading countries with diabetes, five are in Asia (72-73). In 2025, 
India will rank first with 57 million diabetics, followed by China in second place with 38 
million diabetics and Pakistan in 4th place with 14.5 million diabetics (74).  
Table 3. Top Ten Countries for Number of Persons with Diabetes  
 
 
 
 
 
 
 
 
 
 
 (WHO estimates, 1995-2025) 
          
    (1995)     (2025) 
            Country  millions           Country  millions 
1   India   19.4   India   57.2 
2   China   16.0   China   37.6 
3   U.S.A.   13.9   U.S.A.   21.9 
4   Russian Fed.  08.9   Pakistan  14.5 
5   Japan   06.3   Indonesia  12.4 
6  Brazil   04.9   Russian Fed.  12.2 
7   Indonesia  04.5   Mexico  11.7 
8   Pakistan    04.3   Brazil   11.6 
9   Mexico    03.8   Egypt     08.8 
10   Ukraine       03.6   Japan     08.5 
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South Asian (SA) refers to people who originate from India, Sri Lanka, Bangladesh, 
Nepal, Maldives and Pakistan (75). South Asian migrant populations have a two to 
three fold higher prevalence of diabetes than their Europeans counterparts (76). 
South Asians are particularly predisposed to develop diabetes mellitus and coronary 
heart disease (CHD) (28, 77-79). This is mainly due to the fact that South Asians are 
consistent more insulin resistance as shown in various studies (80-82). Important and 
consistent observations related to high prevalence of insulin resistance in South 
Asians show presence of excess body fat and abdominal obesity (83). Although 
South Asians have a lower BMI, they have a higher fat content and more 
subcutaneous fat (84,85) 
 Obesity is a very most important factor associated with insulin resistance. Increase 
of 1/3rd over ideal body weight decreases insulin sensitivity by 40% (86). However it 
is important to note that all obese individuals are not insulin resistant. Obesity is also 
frequently associated with insulin resistance in South Asians settled in other countries 
as well in India (87-91). 
 
 
 
 
 
Figure 2: Features of Metabolic Syndrome / Insulin Resistance in South 
Asians 
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Overall, the prevalence of insulin resistance in South Asians ( 5–50%) is reported to 
be highly variable. This could be due to different methodologies employed by various 
scientists for the assessment of insulin resistance such as Reaven who emphasized 
that the metabolic syndrome was just a small part of the all encompassing insulin 
resistance and the two terms could not be used interchangeably (82).  Moreover, 
tremendous heterogeneity of South Asians in terms of their geographical location and 
partial adaptation of lifestyle of the country of residence, in addition to variations due 
to age, gender, and socio-economic strata may also contribute to this variation in 
prevalence of metabolic syndrome.  
The purpose of making a diagnosis of the metabolic syndrome is to initiate and 
implement lifestyle changes so as to decrease the risk of CVD. Since 15–16% of 
global mortality due to CVD is contributed by India this approach could make a 
significant difference in South Asians to reduce the risk of CVD (92). Although a 
specific risk factor influences the risk that a person will have cardiovascular disease, 
risk factors tend to aggregate and usually appear in combination (79). 
Epidemiological studies have established that multiple risk factors increase the 
probability of cardiovascular morbidity and mortality in a multiplicative fashion. We 
already know that high prevalence of CHD has been observed in immigrant South 
Asians (93-95). What is particularly important in South Asians is that the three 
classical risk factors for CHD – smoking, hypertension and hyper-cholesterolaemia – 
fail to explain the high levels of Coronary Heart Disease (96-97).  
Thus comes the role of insulin resistance as suggested in the study done in South 
Asians (Indian and Pakistani subjects) living in London.  This study demonstrated that 
despite being matched for age and body mass index (BMI) with Caucasians, South 
Asian men had higher waist: hip ratio, higher systolic blood pressure (BP), higher 
insulin levels after glucose load, higher triglyceride levels and lower high density 
lipoprotein (HDL)-levels, all suggesting a high prevalence of the Metabolic Syndrome. 
Thus the CHD risk factors tend to aggregate in those with the metabolic syndrome. In 
addition, type 2 diabetes a CHD risk equivalent was prevalent in 20% of the South 
Asians compared with 5% of Caucasians adding to the CVD risk burden (98).   
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1.3 Pakistan – Country Profile 
 
Pakistan is a poor and underdeveloped country, however government policies since 
2001, bolstered by generous foreign assistance and renewed access to global 
markets have generated macroeconomic recovery in the last five years. The 
government has made substantial macroeconomic reforms since 2000. Poverty 
levels have decreased by 10% since 2001. A brief overview of the country is given 
below: 
1.3.1 Geography: 
 
The country is located in Southern Asia, bordering the Arabian Sea, between India on 
the east and Iran and Afghanistan on the west and China in the north. Geographic 
coordinates are 30 00 North and 70 00 East.  Total land boundaries area with 
countries is 6,774 km; Afghanistan 2,430 km, China 523 km, India 2,912 km, Iran 909 
km while the coastline is 1,046 km.  
Total area is 803,940 sq km of which land is 778,720 sq km & water is 25,220 sq km.  
1.3.2 People:  
 
Population is estimated to be 164,741,000 as of 2007.   
The five main ethnic groups are Punjabi, Sindhi, Pashtun (Pathan), Baloch and 
Muhajir (immigrants from India at the time of partition and their descendants).  
Languages:   
Punjabi 48%, Sindhi 12%, Siraiki (a Punjabi variant) 10%, Pashtu 8%, Urdu (official) 
8%, Balochi 3%, Hindko 2%, Brahui 1%, English (official; lingua franca of Pakistani 
elite and most government ministries), Burushaski and other 8%, 
 
 
Estimates from CIA World Fact Book 
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Figure 3 : Geographic Location of Pakistan 
 
1.3.3 Population Demography:   
 
Thirty seven percent of the country’s population is less than 14 years of age. Around 
58.8% of the population is between 15-64 years while 4.3% of the population is 65 
years or above. The overall median age is around 20.9 years while it is 20.7 years for 
males and 21 years for females.  
Sex ratio is 1.045 male(s)/female for the total population.  
Population growth rate:  1.828%  
Birth rate:    27.52 births/1,000 population  
Death rate:    8 deaths/1,000 population  
Life expectancy at birth for the total population is 63.75 years. It is 62.73 years for 
males and 64.83 years for females. 
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1.3.4 Education 
 
Education in Pakistan is mostly subsidized by the Government from primary schools 
to higher education levels in public universities. The definition of literacy is taken as 
over 15 years of age and able to read and write. This level of literacy for the total 
population is 48.7% while it is 61.7% for males and 35.2% for females according to 
2004 estimates.  
1.3.5 Economy 
 
Pakistan’s economy depends mostly on agriculture. The GDP - per capita (PPP) of 
the country is $2,600 according to 2006 estimates. Unemployment rate is 6.5% plus 
substantial underemployment while 24% of the population lives below poverty line. 
Poverty line is the minimum level of income deemed necessary to achieve an 
adequate standard of living. Definition of poverty varies considerably amongst nations 
and the definition of poverty line is significantly higher in developed nations than in 
developing nations. Here it is taken as one US dollar. 
1.3.6 Lifestyle and Physical Activity 
 
Lifestyle of the people is different according to rural and urban settings. Apart from 
household work the women in the rural areas also help their men in the fields and in 
looking after cattle. Compared to this the people in city are exposed to a easier way 
of daily life. Pakistani people do not have a tradition of doing extra physical exercise 
apart from the requirements of their daily work. 
1.3.7 Diabetes in Pakistan 
 
The World Health Organization estimated that there would be approximately 5.2 
million diabetics in Pakistan in the year 2000, ranking it at sixth place among 
countries with the highest number of diabetics (74). The current scenario is that there 
are 6.9 million diabetics in Pakistan according to International Diabetes Federation 
(31). This number is predicted to increase to 14.5 million by the year 2025-2030 (31, 
74). The predictions are modeled upon the reported prevalence of T2DM in the 
national survey conducted by the Diabetic Association of Pakistan (DAP) in 
collaboration with the World Health Organization (WHO) during the 1990s (99-101). 
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Conducted in urban and rural areas in the four provinces (NWFP, Baluchistan, 
Punjab and Sindh), the national survey used WHO guidelines for the diagnosis of 
T2DM and impaired glucose tolerance (IGT) in over 5,600 persons 25 years and 
older. The overall prevalence of T2DM among men and women was reported as 
11%, with overall abnormal glucose control of 22%. A summary of the results is given 
in table 4 below. A higher prevalence of obesity and IGT was observed among 
women as opposed to men and a relatively higher prevalence of diabetes and IGT 
was found in younger age groups (99-101) as compared to western populations. 
Nearly half of the subjects in these surveys did not know they had diabetes.  
 
Table 4. Pakistan National Diabetes Survey 
 
Province Diabetes(%)        IGT(%) 
Sindh                    (Rural) 
                             (Urban) 
13.9 
16.5   
11.2 
10.4 
Baluchistan        (Rural) 
                             (Urban) 
07.5 
10.8   
07.4 
10.4 
NWFP          (Rural) 12.0 09.4 
Punjab          (Rural)  
                              (Urban) 
06.2  
13.7  
05.6 
10.3 
Overall   11.5  9.3 
                             
1.3.8 CVD in Pakistan 
 
Data on CVD in Pakistan is sparse, with a few hospital-based descriptive studies 
providing the only estimates of CVD available. One such study on acute myocardial 
infarction (AMI) based on admissions to two tertiary care centers in Lahore and 
Sheikhupura over a one year period ending in 1993 concluded that the prevalence of 
symptomatic IHD in younger age group (< 35 years) is about 4% in Lahore and about 
6% in Sheikhupura (102).  
  
Risk Factors Associated with CVD 
These risk factors can be classified into two categories:  
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1 Those that have been proven to be causal (risk factors). These markers could 
be classified as predisposing (e.g., obesity which may work through raising 
blood pressure, glucose, and lipids) or direct (e.g., smoking).(103)   
 
2 Those that have shown association with CHD but for whom a cause and effect 
association is yet to be proven (risk markers).(103) 
 
Table 5.  Risk Factors that are causally linked 
1. Tobacco consumption 
2. Elevated LDL 
3. Low HDL 
4. High Blood Pressure 
5. Elevated glucose 
6. Family history 
7. Physical inactivity* 
8. Obesity* 
 
Table 6. Risk markers that show associations: 
1. Low socioeconomic status* 
2. Elevated prothrombotic factors: fibrinogen, PAI-1 
3. Markers of infection or inflammation 
4. Elevated homocysteine 
5. Elevated lipoprotein (a) 
6. Psychological factors (depression, anger proneness, hostility, stress, acute life-
events) and breakdown in social structure (loss of social support and cohesion)* 
* Predisposing risk factors: A predisposing risk factor is presumed to work, at least in part, 
through an impact on other risk factors that act directly. 
PAI indicates Plasminogen activator inhibitor. 
(Adopted from Global Burden of Cardiovascular Diseases - 103) 
 
1.4 Statement of Problem 
In view of the increasing prevalence of type 2 diabetes in Pakistan, it is reasonable to 
postulate that there is a increasing epidemic of metabolic syndrome going on in 
Pakistan at the moment. Since the metabolic syndrome is a long-term process that 
starts early in life and is involved in the patho- physiology of type 2 diabetes and 
atherosclerosis, vigorous early management of the syndrome will have a significant 
impact on the prevention of both diabetes and CVD (3,5,85–87).   
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A study done in 400 cardiac patients at a tertiary cardiology unit in Pakistan 
according to ATP III definition showed a prevalence of 44% metabolic syndrome 
(104). While in another study done in type 2 diabetic subjects in Karachi, subjects 
had 46% metabolic syndrome according to the WHO definition (105).  
Epidemiological studies have demonstrated the associations between these risk 
factors with the twin epidemic of T2DM and CVD. 
Community-based interventions to reduce these risk factors have proven effective in 
developed countries for preventing T2DM and CVD, with a limited number of studies 
in developing countries indicating that similar gains are potentially achievable here as 
well. Diabetes prevention and control is particularly relevant in Pakistan; increased 
inherent predisposition, younger age of onset, lack of capacity to effectively treat the 
condition at the primary healthcare level and lack of equitable access to healthcare 
for possible complications makes a strong case for investment in diabetes prevention 
and control (106-107). 
The awareness of ethnicity as a potential independent risk factor for chronic disease 
has clinical importance since lower thresholds would have to be considered for 
primary prevention strategies in certain ethnic groups (83,84).  The current study will 
establish baseline values for insulin levels and assess the prevalence of metabolic 
syndrome among adults in urban Karachi and lay the foundations for future 
intervention studies of primary prevention of Type 2 diabetes and CVD. 
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1.5 Research Questions and Objectives of the Study   
1.5.1 Research Questions 
 
1. What is the prevalence of metabolic syndrome based upon WHO, ACE, EGIR, 
modified ATP III and IDF definition in this Pakistani population?  
 
2. What is the prevalence of diabetes and other forms of abnormal glucose 
tolerance in subjects aged 25 years and above in Karachi, Pakistan?  
 
3. What is the distribution and relationships of cardiovascular disease and its risk 
factors in this population with metabolic syndrome? 
 
4. What is the insulin resistance for our population? 
1.5.2 Main Objective 
 
9 To determine the prevalence of metabolic syndrome in a sample of adults 
aged 25 years and above from an urban population of Karachi. 
1.5.3 Specific Objectives 
 
More specifically, the objectives of the study were to: 
 
¾ Estimate and compare the differences in prevalence of metabolic syndrome 
based upon WHO, ACE, EGIR, modified ATP III and IDF definition in Pakistani 
population.  
 
¾ Estimate the prevalence of diabetes and other forms of abnormal glucose 
tolerance and association of IFG with metabolic syndrome.  
 
¾ Assess the distribution and relationships of cardiovascular disease and its risk 
factors with metabolic syndrome. 
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1.6 Justification of the Study 
 
 It is recognized that the features of the Metabolic Syndrome can be present up 
to 10 years preceding Type 2 diabetes and CVD (88). The driving force behind 
high diabetes and CVD incidence in South Asians could be having the 
Metabolic Syndrome.  
 
 The rising prevalence of obesity and metabolic syndrome has received 
increased attention in recent years since both place individuals at risk for Type 
2 diabetes and CVD. The detection of conventional risk factors associated with 
Metabolic Syndrome is important for primary prevention programs for diabetes 
and CVD. 
 
 The combination of the components of the metabolic syndrome may give the 
epidemiologist an instrument with a good predictive power for future diabetes 
and CVD detection. 
 
 The metabolic syndrome may also provide the primary care physician an 
integrative view linking conditions frequently seen together but thought 
unrelated in the past such as hypertension and low high-density lipoprotein 
cholesterol.  
 
 Thus, the metabolic syndrome could possibly be a fundamental part of the 
public health policy as prospective data have shown that treatment of its 
components delays or prevents occurrence of disease.  
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2.1 Scope of study 
 
This study was designed as a prevalence survey for metabolic syndrome among 500 
randomly selected households in Lyari. We also assessed the prevalence of diabetes 
and cardiovascular disease in this population.  
2.2 Research Setting  
 
Lyari is one of the oldest and most densely populated part of Karachi city (estimated 
population of 13-14 million in 2004). Lyari’s approximately 700,000 residents form an 
extremely diverse community, representing almost every cultural and ethnic groups 
found in Pakistan. The area was originally inhabited by Baluchi tribes that moved 
here from around the Makran coast during the 18th century, joined soon thereafter by 
Sindhi tribes from around the Indus river and delta. Large migrant communities from 
Gujrat and Bihar first settled in Lyari following the partition of British India. Economic 
migrants, mostly men, from the Punjab and North West Frontier Province (NWFP) 
arrived during the 60s and 70s, followed by refugees from the war in Afghanistan 
during the 80s. These migrants have gradually brought their families to settle here as 
well. Significant Christian and Hindu neighbourhoods are scattered in between the 
majority Muslim population. There is similarly a wide spectrum of socioeconomic 
groups. 
2.3 Lyari Town Geographical Information System 
 
Lyari Town Geographical Information System was made by Population Census 
Office, Statistics Bureau Sindh, National Database and Registration Authority 
(NADRA) and  Interactive Research and Development, a private research 
organization to define the geopolitical boundaries and population density of Lyari 
Town (estimated 2004 population of 700,000). This was done by dynamically linking 
the national census database to a purpose built geographical information system 
(GIS).  A year-long, detailed physical survey of Lyari Town was then undertaken 
using available plot maps, most of which were over 20 years old. Although these plot 
maps required extensive and careful updating, the final results of the physical survey 
were impressive; all household structures were given a unique identification number, 
along with all health, education and other civic facilities available to its residents. The 
edited plot maps were then newly traced, with the unique number ascribed to each 
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household clearly visible and commercial and civic services clearly high-lighted. The 
new maps were finally digitized using a geo-referenced satellite image of Lyari town 
at 1 meter resolution as shown in figure 4. The objective of developing the Lyari Town 
GIS has been to lay the infrastructure for the longitudinal follow-up of households to 
assess indicators that may be of interest to researchers, including determining the 
community-based prevalence of chronic diseases among adults as has been done by 
our group.  
 
 
 
Lyari Town: Population 699,595 
Ikonos 1 m Resolution; Vector Referenced ±10 ft
  
Figure 4: Lyari Town 
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Lyari Town: 85,520 Households
500 Households Randomly Selected
 
Figure 5: Randomly Selected 500 Households 
2.4 Study Population 
 
We generated a computerized random sample of 500 households from among the 
85,520 households in Lyari Town as shown in figure 5. There were 11 union councils 
or subdivisions of Lyari Town where the samples were taken from ensuring that each 
union council had equal opportunity to be represented in the sample selection. We 
expected approximately 1000 adult men and women 25 years and above in the 500 
households in Lyari. If members of a household that had been selected refused to 
consent to household interviews, we knocked on the third door to the right of that 
house (while standing facing the door of the original house) and seeked consent 
there. If we were refused again, we knocked on the next consecutive door to the right 
and repeated this process until we had enrolled a household from the neighbourhood 
of the original household selected. 
Individual members within households also reserve the right to refuse participation in 
the study. Assuming a 10% refusal rate (by members within the household at the time 
of interview) and another 10% refusal rate by those who decline to provide consent 
for a blood test, we expected at least 810 individuals to participate in this study. 
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2.5 Criteria for Inclusion and Exclusion 
 
¾ All adults 25 years and above from the households selected and who gave 
their informed consented were included in the study.  
 
¾ Persons with physical or intellectual disabilities that precluded participation in 
the study were not included.  
 
¾ Those were also excluded who had resided in the current address for less 
than 6 months prior to the survey. 
 
2.6 Sample Size 
 
In planning phase the following assumption was made by the research group;  
 
1) Assuming that the prevalence of T2DM to be 11% in this population 
(prevalence in urban populations is actually higher),  
2) the size of the population from which the study sample is to be selected 
(persons 25 years and above in Lyari Town) is 244,000,  
3) the worst acceptable result is ±1.5% from the true population value, our study 
would require a sample of at least 713 individuals to have 80% power to detect 
the true population value.  
4) Since the prevalence of metabolic syndrome is assumed to be higher than that 
of diabetes we believe this sample size would be sufficient for assessing 
metabolic syndrome in our population. 
In the field we were able to interview 867 individuals; more than the required number 
but only 363 individuals gave blood samples leaving us with less than the required 
numbers at the end of the study giving us 40 – 45% power to detect true population 
value.    
2.7 Research Design  
2.7.1 Survey protocol and procedures 
 
The survey activities were conducted over a period of 6 months from July to 
December 2004. A Geographical Imaging Systems (GIS) as already described, 
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previously developed for Lyari Town with unique identification numbers ascribed to 
85,520 households was used.  
The survey activities were divided into two phases—the household interview plus 
physical examination and blood sample collection. 
A household was defined as including all those who shared a kitchen. Five hundred 
households were randomly selected through the GIS software and maps to these 
households were generated for 9 field teams. A field team comprised of one or two 
medical students, a female health worker and a male health worker. Surveyors from 
the GIS teams worked as guides for 2-3 teams in a given area. All teams and 
surveyors were supervised by a medical doctor acting as the field coordinator.  
2.7.2 Household census and interview 
 
Twelve medical students conducted these household visits with assistance from 8 
health workers from Lyari Community Development Project – a local welfare 
organization. Once a household was located, medical students identified themselves 
to the oldest male or female member present and informed them of the objectives of 
the survey. All adults 25 years and older were invited to participate after providing 
signed consent. In case of illiterate participants, the consent form was read out to 
them and a thumb print procured in the presence of a household member or 
neighbour as witness.  
Field work entailed afternoon visits to the selected household by a field team (medical 
students and health worker), introduction to the purpose of the research study, 
consent, interviews and physical measurements (including weight, height, waist and 
hip circumference, blood pressure).  
The interviewers made a minimum of 2 visits and up to 5 visits before a household 
was classified as a non contact. Where possible, at each participating household a 
personal interview was conducted with every adult member aged 25 years and above 
who met the eligibility requirements.  
At the end of the household visit, all adults 25 years and above were asked to 
undertake an 8 hour fast for blood tests (fasting blood sugar and lipid profile) that was 
collected at home on Saturday and Sunday mornings. All adults were provided with a 
urine collection bottle and asked to collect a mid-stream urine specimen for tests (pus 
cells, proteinuria and microalbuminuria) on the morning of  their blood test date. 
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2.7.3 Questionnaire 
 
The adults present in each household were administered a survey form 
(Questionnaire) which consisted of 3 main parts (Appendix - 1).  
a) Part A collected information about the entire household and was same for all the 
persons living in a specific household. It consisted of 4 sections.  
b) Part B of the survey form collected information about personal and family history 
of the individual persons in each household and consisted of 6 sections. Part B of 
the survey form consisted of question forms in Urdu for easy understanding of the 
community.  
c) Part C collected anthropometric information about the individual persons and also 
lab reports were written in this section.  
 
1. Part A  
It consisted of 4 sections and collected information about the entire household 
individuals.  
Section A1 asked questions about household demography including total number of 
persons residing in the house, their relationship with head of household, ethnicity and 
place of birth etc.  
Section A2 had 8 questions about the household diet with reference to fat, oil and 
salt intake.  
Section A3 had 10 questions  to assess the socioeconomic status.  
Section A4 showed the morbidity and mortality of each household. This also 
included the type and cost of treatment as well as the number of deaths during the 
last 3 years.  
 
2. Part B  
It consisted of 6 sections and collected information from individual persons about 
personal and family history. It contained question forms in Urdu for easy 
understanding by the community.  
Section B1 consisted of 24 questions in Urdu on personal demographics and 
personal medical history of each person interviewed.  
Section B2 consisted of 16 questions about family medical history.  
Section B3 contained 29 questions about tobacco consumption and smoking.  
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Section B4 had 40 questions about personal dietary habits with a list of commonly 
used food items. 
Section B5 consisted of 9 questions on chest pain on physical exertion (Rose).  
Section B6 had 8 questions about physical activity and exercise during the last 7 
days. 
 
3. Part C  
Collected anthropometric data and included measurements of weight, height, waist 
and hip circumference. Participants were asked to wear light clothing and take off 
their shoes during anthropometry measurements. Height was measured to the 
nearest cm and weight to the nearest 0.1 Kg. Weight was taken with a standardized 
scale and height with a standardized measuring stick. Waist circumference was 
measured as the mid point between the iliac crest and the lower margin of the ribs. 
Blood pressure was take by a medical student or doctor at least twice with 20 minute 
intervals, after ensuring that at least 30 minutes had passed since tea or tobacco 
were last consumed. A third BP measurement was taken if one or both of the first two 
readings were above the cutoffs for a diagnosis of hypertension.  
 
2.7.4 Blood Samples 
 
Specimens were collected at home on Saturdays and Sundays by five mobile teams 
consisting of two phlebotomists each. At the time of blood collection on Saturdays 
and Sundays, all participants were asked to provide consent for blood tests for fasting 
blood glucose and lipid profile and urine for proteinuria. We also asked for consent for 
tests to be conducted on stored sera based on future research protocols, including 
genetic studies. Aliquots of serum from all participants were stored at -70 degrees 
Celsius for up to 5 years.  
All blood samples were collected in two separate test tubes; a red caped vacutainer 
and green capped fluoride tube. A total of 12 cc of blood was taken from each 
patient. 10 cc was place in the vacutainer for analysis of Lipid profile and insulin 
serum levels and remaining 2cc was placed in the NaF test tube for analysis of 
fasting glucose.  
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Within 1 hour of collection the blood was centrifuged and separated; tests done by 
the Vitalab Selectra Analyzer for; 
1. Glucose 
2. Cholesterol 
3. Triglycerides 
4. HDL-Cholesterol  
5. LDL-Cholesterol  
6. Insulin 
Fasting blood glucose and lipid profile were done by GOD PAP method and CHOD 
PAP method respectively. Insulin levels were done by Elisa method.  
2.7.5 Urine Samples 
 
This was collected by the respective subject on the morning of collection. They were 
advised to keep the specimen in a cool and shaded area. Urine tests included a 
qualitative determination of proteinuria and a quantitative measurement of 
microalbuminuria. 
 
2.8 Statistical analysis 
 
All data was recorded on forms developed using TeleForm® Version 6.01, an optical 
character recognition software. Forms were scanned, read and verified using 
TeleForm® Version 6.01 and exported into an SQL database. Later this data was 
converted into the software package SPSS version 11.5 (Statistical Package for 
Social Sciences) for analysis.  
The main variables for analysis included age, gender, socioeconomic and ethnic 
groups, fasting glucose and insulin levels, lipid profile, proteinuria and 
microalbuminuria, hypertension, body mass index, waist-hip ratio, mid-abdominal 
circumference, smoking exposure and family history of disease.  Some of the other 
risk factors to be included in the analysis were physical activity and diet.  
We started with frequency analysis of all the variables in the survey form and cross-
tabulation of the main variables. We estimated the odds of impaired glucose control, 
high risk lipid profiles, proteinuria, microalbuminuria, hypertension, high body mass 
index, high waist-hip ratio, large mid-abdominal circumference, smoking exposure 
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and family history of disease by age, gender and metabolic syndrome group, using 
chi square for categorical variables. In addition, difference in the means of continuous 
variables between these groups will be tested using the t-test or ANOVA.  
 
2.9 Ethical Considerations 
 
2.9.1 Ethical Clearance 
 
The study protocol was approved by the institutional review board of the Baqai 
Institute of Diabetology and Endocrinology (BIDE) and by the Local Ethics Committee 
of  the Lyari Community Development Project (LCDP).  
The study protocol had also been sent to the Norwegian Ethics Committee for 
approval. 
2.9.2 Informed Consent 
 
Informed consent is a prerequisite for all research involving human subjects. Verbally 
and in writing, subjects were informed about the purpose and scope of the study, the 
benefits and risks of the study, how the results will be used and reported and the 
method of confidentiality that will be used in reports. Since all the subjects were 
interviewed from a structured questionnaire; questions did not probably change from 
subject to subject.   
All participants were required to give their informed consent voluntarily and the study 
was carried out in accordance with the Declaration of Helsinki as revised in 2000.  
Participation for household interview and laboratory tests required the consent form 
to be signed in front of a witness. All participants reserved the right to withdraw from 
the study at any time, even if they have previously given consent to be part of study. 
The findings were treated with highest possible degree of confidentiality. Each 
subject was given a unique identity number. 
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3.1 Results  
 
In this chapter descriptive analysis of the main variables present in the survey 
questionnaire will be presented followed by prevalence of glucose tolerance and 
distribution of cardiovascular disease risk. Secondly prevalence of the metabolic 
syndrome based on different definitions will be compared. Finally percentiles of 
insulin levels in the community will be defined. 
3.1.1 Part A: Household Section of Questionnaire 
 
The total number of households visited was 532 in which 3608 persons resided. Of 
these 51% were males while 49% were females. Out of these 3608 persons 1493 
were > 25 years of age.  Of these 734 (49.2%) were males while 759 (50.8%) were 
females. 
 
 
Figure 6: Household Survey – No of Eligible Persons 
 
 
3.1.1.1 Section A1 asked questions about household demography including total 
number of persons residing in the house, their relationship with head of household, 
ethnicity and place of birth.  
Persons in Households n = 3608 
≥ 25 years 
n=1493 
<25 years 
n=2115 
Excluded from Study 
Blood samples given 
n=363 
Consent given 
n = 867 
Households
n=532
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Figure 7: Age and Gender distribution of Sample (n=3608)   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Looking at the ages of the persons residing in these 532 households a total of 154 
children were less than 1 year of age.   
Figure 8: Ethnicity in Households (n=3608) 
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Figure 9: Division of the population on the basis of language (n=3608)  
 
3.1.1.2 Socio-demographic characteristics 
The Socio-demographic characteristics of the Households are given below  
 
Table 7: Socio-demographic characteristics of the Households 
 
Variables n % Mean Std. Dev. 
Gender 3608    
Male  
Female 
1840 
1768 
50.8 
49.2 
  
Age distribution      
Male 
< 25 years 
≥ 25 years 
Female 
< 25 years 
≥ 25 years 
 
1116 
734 
 
999 
759 
 
60.3 
39.7 
 
56.8 
43.2 
23.59 
 
 
24.43 
17.21 
 
 
17.10 
Residence in Same Household   21 21 
≤ 10 years 
11 - 30 years 
> 30 years 
1660 
1226 
722 
46.0 
34.0 
20.0 
  
     
24.3
17.7
0.2 0.8
3.4
15.3
1.7
14.1
9.8
1.1
6.8
4.0
0.90
5
10
15
20
25
Linguistic Consideration %
24.3 17.7 0.2 0.8 3.4 15.3 1.7 14.1 9.8 1.1 6.8 4.0 0.9
Sindhi Baluchi  Jadgal Brohi Gujrati Memon Kathwri Urdu Punjabi Siraiki Pushto Hindko Others
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Variables n % Mean Std. Dev 
Residence in Lyari   35 19.6 
≤ 5 years 
6 -10 years 
11 – 15 years 
16 – 29 years 
≥ 30 years 
325 
289 
289 
721 
1984 
9 
8 
8 
20 
55 
  
No. of person HH     7.7 5.4 
≤ 7 
8 – 10 
11 – 15 
≥ 16 
1716 
984 
655 
253 
47.56 
27.26 
18.00 
7.01 
  
Marital Status     
Single 
Married 
Divorced / Separated / Widowed 
2165 
1263 
180 
60 
35 
5 
  
Education     
Illiterate 
Madressa / Primary 
Secondary / Matriculation 
Intermediate / Bachelor / Masters
1075 
1263 
928 
238 
29.8 
35.0 
25.7 
6.7 
  
Employment Status     
*Student or unable to work 
Unemployed 
¥Employed 
 Housewife 
Did not know 
1504 
660 
938 
437 
69 
41.7 
18.3 
26.0 
12.1 
1.9 
  
 
* it include students/too young, physically handicapped and bed ridden. 
¥ includes working on daily wages, self employed and working for monthly wages. 
 
Sixty five percent of the persons were born in lyari while 18% were born in other 
areas of Karachi. The rest (17%) were born outside Karachi.  
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Figure 10: age distribution for place of birth 
 
At five year differences of age we observed that the older the person more the 
chances of his being born at home. 
On the basis of home or hospital delivery we found that 52% of all individuals were 
born in hospital or maternity home while the rest were born at home.  
 
3.1.1.3 Section A2 gathered information about the household diet with reference to 
fat, oil and salt intake. In 57% households at least 6 persons eat at home while in 
31% at least 10 persons eat at home while in 10% households more than 12 persons 
eat at home. On an average 7 persons per household eat at home every day. 
 
Table 8: Use of Fat and Salt in Households 
Variable n = 532 % Average Consumption per 
month 
Type of fat for cooking    
Banaspati Ghee  
(Saturated And Trans fatty acids) 
Cooking Oil 
Combined Banaspati Ghee and Oil
Other Oils 
80 
 
218 
221 
13 
15.0 
 
41.0 
41.5 
2.5 
 4.0 + 3.0 Kgs per month  
 
 4.9 + 3.4 Kgs per month  
    
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
00-04 00-09 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-69 60-64 > 65 
Home Hospital 
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Salt use per month    
< 1000 gm 
1000 – <1500 gms 
1500 – <2000 gms 
≥ 2000 gms 
211 
301 
10 
10 
39.7 
56.5 
1.9 
1.9 
 
 
 
3.1.1.4 Section A3 had questions to assess the socioeconomic status.  
Although 98% houses had permanent walls only 86% had permanent roof. Around 
59% had their own houses while the rest were on rent. The average rent was 
estimated to be around 1,500 Pakistani rupees per month.  
Figure 11: Type of Residence 
 
 
 
 
 
 
 
 
 
 
 
 
 
Taking into account the number of rooms in a household 29% were living in a house 
having > 3 rooms excluding the kitchen and toilets. A separate kitchen was present in 
66% of the households while the rest used either part of a room (13%) or the open 
space (20%) as a kitchen. 
As regards the water sanitation condition in each household nearly 90% had bathing 
water indoors. Of theses bathing facilities 80% was also used for drinking purposes 
will the remaining 20% houses used other sources of drinking water. 
As regards the hygiene and sanitation condition we asked about the type of toilet 
used to assess waste disposal facility. Around 79% used a flush latrine at home while 
1% used a latrine outside the house (80% used a flush latrine). Around 11% used a 
close pit while 5% used a bucket and 4% used to defecate in the open space.  
36
1536
13
House < 80 sq. yards House > 80 sq. yards flat <= 2 rooms flat > 2 rooms
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We also collected data about the household items available in the households visited.  
Figure 12: Household Items 
 
 
 
Almost all (99.6%) households had electricity while 95.6% had sui gas at home. 
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Table 9: Monthly and Annual Income 
 
Monthly Income in Pak. Rupees 
at Household level 
n % Average Income 
per month 
≤ 3000  
>3000 - <5000 
≥ 5000 - <8000 
≥ 8000 - <10000 
≥ 10000 
156 
103 
158 
24 
91 
29.3 
19.4 
29.7 
4.6 
17.0 
 
5,000 
 
The average annual income was calculated to be Pakistani Rupees 54,500.  
 
3.1.1.5 Section A4 showed the morbidity and mortality of each household. This also 
included the type and cost of treatment as well as the number of deaths during the 
last 3 years In 33% of the households a person had been sick during the last 15 
days. Twenty five percent had one person sick during last 15 days while 5% had 2 
persons sick during this period. Three percent households had 3 or more persons 
sick during the last 15 days.  
Table 10: Mode of Treatment 
Mode of Treatment 
No treatment Govt. Hospital 
or Dispensary 
Private 
Hospital 
Family 
Physician 
Cost / Patient 
Mean + SD 
     
5.9% 8.1% 13.0% 73.0% 878 + 2078 
 
With regards to the mortality in households, in 10% of the households someone died 
during the last 3 years. Twenty one percent of all deaths were in children less than 
one year old. 
3.1.2 Part B: Individual Section of Questionnaire 
 
A total of 871 persons were approached out of which 867 persons > 25 years gave 
their consent to be interviewed for our survey (Response rate 99.5%). Thus of all the 
persons > 25 years residing in the 532 selected households 867 persons were 
interviewed by the field teams. Part B consisted of 6 sections which collected 
information about personal and family history from these individual persons.  
3.1.2.1 Section B1 consisted of on personal demographics and personal medical 
history of each person interviewed. The following table gives a summary of the 
questions asked  
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Table 11: Personal Demography of Individuals  
Variables n = 867 % Mean + SD
Ever Checked your Blood Pressure?    
Yes 
No 
702 
165 
81.0 
19.0 
 
Ever told by Physician you have high blood pressure? 
Yes 
No  
172 
490 
25.9 
74.1 
 
Did Physician prescribed any medication for high BP? 
Mean Age 
Yes  
No 
Did not reply (not included in %) 
 
130 
27 
15 
 
82.8 
17.2 
38.5 + 14.7
Ever told by Physician you have a heart disease?    
Yes 
No  
51 
802 
5.9 
94.1 
 
What was the Heart diseases?    
Mean Age 
Angina Pectoris 
Heart attack 
Other 
 
27 
19 
5 
 
52.9 
37.2 
9.8 
42 + 15 
Ever told by Physician you have kidney disease?    
Mean Age  
Yes 
No 
 
54 
794 
 
6.4 
93.6 
30.9 + 12 
Ever told by Physician you have diabetes?    
Mean Age 
Yes 
No 
 
46 
804 
 
5.4 
94.6 
48 + 14 
How your DM was diagnosed?    
Had symptoms 
Through screening 
30 
16 
65.0 
35.0 
 
What medications were prescribed to control your DM? 
Diet only 
Insulin  
Tablets 
4 
3 
39 
9.5 
4.8 
85.7 
 
Have you ever had an attack of stroke?    
Mean Age 
Yes 
No 
 
21 
833 
 
2.5 
97.5 
39 + 24 
Ever told by Physician you have Asthma/lung disease? 
Yes 
No 
56 
568 
8.9 
91.1 
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3.1.2.2 Section B2 consisted of questions about family medical history. A total of 856 
persons answered this section. Mean age was 40.5 + 14 years.  
Table 12: Family Medical History 
Variables N=856 % 
Consanguineous Marriage of parents   
Yes  
No 
355 
451 
44.1 
55.9 
Immediate family member patient of hypertension?   
Yes 
No 
Don’t Know 
223 
421 
40 
37.0 
69.7 
3.3 
Which family member?   
Parents 
Offspring 
Sibling 
182 
1 
40 
81.8 
0.3 
17.9 
Immediate family member patient of heart disease?   
Yes 
No 
Don’t Know 
115 
488 
7 
18.8 
80.0 
1.1 
Which family member?   
Parents  
Offspring 
Sibling 
93 
4 
18 
80.8 
3.2 
16.0 
Immediate family member patient of Diabetes Mellitus? 
Yes 
No 
Don’t Know 
131 
424 
58 
21.3 
69.1 
9.6 
Which family member?   
Parents 
Offspring  
Sibling 
3 
95 
33 
2.3 
72.3 
25.4 
Immediate family member had an episode of stroke ? 
Yes 
No 
Don’t Know 
55 
546 
1 
9.1 
90.7 
0.2 
Which family member?   
Parents 
Offspring  
Sibling 
49 
1 
5 
89.9 
1.3 
8.9 
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The most common known cause of death was heart attack in both parents. 
Figure 13: Cause of Death 
Table 13: Parental Age at Death  
 
Mother  Mean (SD) age at Death Father  Mean (SD) age at Death 
43 % 59.7 (± 19.2) years 63 % 62.5 (± 16.5) years 
 
3.1.2.3 Section B3 contained questions about tobacco consumption and smoking. It 
was answered by 856 persons. It was interesting to note that the age of first use of 
these items ranged from 10 to 30 years of age with a mean around 20 years. This 
section contained details of four different types of tobacco use as given below. 
Table 14: Tobacco Consumption 
Variable  n % mean Std. Dev.
Ever smoked cigarettes/cigar/beddi?     
Yes 
No 
62 
555 
10.0 
90.0 
    
Age when started smoking cigarette/cigar/beddi? 22 11.5 
≤ 18 years 
> 18 -  ≤ 25 years 
> 25 years 
39 
10 
13 
63.3 
16.5 
20.2 
  
Do you currently smoke cigarette/cigar/beddi?   
Yes 
No 
41 
21 
66.0 
34.0 
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Variable  n % mean Std. Dev.
Age when stopped smoking cigarette/cigar/beddi?   
   45 20  
Are these cigarettes filtered or non-filtered?     
Filtered 
Non-filtered 
53 
09 
85.5 
14.5 
    
Average cigarette/cigar/beddi smoked in a day? 11 8 
1 -5 
6 – 10 
11 – 15 
16 – 20 
> 20 
20 
10 
03 
27 
02 
32.2 
16.1 
4.8 
43.5 
03.2 
  
Ever smoked huqah/pipe?     
Yes 
No 
53 
562 
8.6 
91.4 
    
Age when started smoking huqah/pipe?   20 9.4 
≤ 18 years 
> 18 -  ≤ 25 years 
> 25 years 
28 
16 
09 
53.6 
29.3 
17.1 
  
Do you currently smoke huqah/pipe?     
Yes 
No 
29 
24 
54.7 
45.3 
  
Age when stopped smoking huqah/pipe?     
    28.6  14.5 
Ever use naswar?     
Yes 
No 
38 
576 
06.2 
93.8 
    
Age when started using naswar?   20 11.3 
≤ 18 years 
> 18 -  ≤ 25 years 
> 25 years 
23 
06 
07 
63.9 
16.7 
19.4 
  
Do you currently use naswar?     
Yes 
No 
34 
04 
89.5 
10.5 
  
 
  
Ever chewed pan with tobacco?     
Yes 
No 
126 
492 
20.4 
79.6 
    
Age when started chewing pan with tobacco?  23 11.7 
≤ 18 years 
> 18 -  ≤ 25 years 
> 25 years 
40 
50 
36 
31.5 
39.4 
29.1 
  
Do you currently chew pan with tobacco?     
Yes 
No 
110 
016 
85.3 
14.7 
  
Age when stopped chewing pan with tobacco?  32.5 14.9  
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Average No. of pan with tobacco chewed in a day?  07 08 
1 -5 
6 – 10 
11 – 15 
16 – 20 
> 20 
61 
43 
08 
02 
07 
50.4 
35.5 
06.6 
01.7 
05.8 
  
 
3.1.2.4 Section B4 had 40 questions about personal dietary habits including a list of 
33 commonly used food items used on daily, weekly or monthly basis.  
Table 15: Food items used on daily, weekly or monthly basis 
Items Weekly Daily 
 
% Not 
using 
Monthly 
Use (n) n % use Days n % of use 
Eggs 38.0 444 338 96.0 4 431 88.0 
Parhata 35.6 75 60 53.0 1 83 94.0 
Nan 31.1 118 125 80.0 2 45 82.0 
Halwa Puri 62.9 88 54 89.0 1 11 100.0 
Milk 71.0 48 56 57.0 1 72 97.0 
Skim Milk 68.0 51 78 54.0 1 110 94.0 
Cream 81.2 53 47 47.0 1 38 100.0 
Custurd 61.0 254 59 64.0 1 11 64.0 
Ice cream 59.0 259 69 64.0 1 12 92.0 
Yougurt 29.0 166 322 52.0 1 113 94.0 
Sweet Lasi 59.0 165 132 65.0 1 41 95.0 
Lassi 58.0 161 145 58.6 1 51 94.0 
Margirine 92.7 21 23 70.0 1 12 100.0 
Butter 80.0 72 65 58.5 1 28 96.0 
Mutton 56.2 130 228 52.0 1 12 100.0 
Beef 18.7 109 561 71.0 2 35 85.7 
Chicken 9.9 165 600 79.5 2 20 70.0 
Fish 17.7 235 444 52.0 1 25 80.0 
Prawns 56.0 211 162 78.4 1 7 85.7 
Organ Met 54.3 264 114 75.0 1 11 91.0 
Junk Food 60.3 224 98 56.0 1 21 95.0 
Cook Veg 8.4 56 651 65.0 2 94 87.0 
Cook Potat 10.0 58 508 64.0 2 198 95.0 
Raw Veg 30.6 112 315 76.0 2 159 92.5 
Fried Rice 11.5 269 464 69.8 1 27 81.5 
Legumes 3.6 66 689 75.0 2 63 94.0 
Fruits 26.4 186 252 73.0 2 171 97.0 
Fruit Juice 76.0 65 97 70.0 1 31 97.0 
Bakery Itm 42.5 121 190 81.0 2 166 96.0 
Desi Sweat 65.0 233 42 69.0 1 11 91.0 
Fried Items 36.1 311 205 80.0 2 26 96.2 
Dried Fruit 76.3 133 45 91.0 2 15 100.0 
Choc tofee 81.5 60 30 77.0 2 58 96.6 
Others 72.0 3 4 100.0 1 31 74.0 
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Information was also collected about use of additional salt on food, salad and tea 
from the 867 subjects.  
Figure 14: Use of Additional Salt 
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3.1.2.5 Section B5 consisted of questions on chest pain on physical exertion. 
Only 18% reported any sort of chest pain.  
Table 16: Chest pain on physical exertion 
 n = 867 % 
Chest Discomfort   
Yes  
No 
156 
711 
18.0 
82.0 
On exertion or climbing stairs   
Yes  
No 
93 
51 
10.7 
5.9 
On walking Straight    
Yes  
No 
53 
55 
6.1 
6.3 
What do you do when pain occurs?   
Carry on walking  
Slow down and Stop 
31 
67 
3.6 
7.7 
Relieved on Standing Still?   
Yes  
No 
39 
26 
4.5 
3.0 
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Relieved in   
< 10 minutes 
> 10 minutes 
31 
26 
3.6 
3.0 
Pain in Left Anterior Chest  28 3.2 
Pain in Left Arm 2 0.2 
Pain in Sternum 22 2.5 
Any other Site 19 2.2 
 
3.1.2.6 Section B6 had questions about physical activity and exercise during the last 
7 days. 
This was asked to a total of 867 persons. A majority of the people were not physically 
active.  
Figure 15: Physical Activity 
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Table 17: Average duration of Physical Activity 
 
Physical Activity n Average n Average 
 Days/ week Hours / day 
Vigorous Activity 130 4.5 + 2.5 62 2 + 1 
Moderate Activity 345 5 + 2.5 254 2.2 + 1.6 
10Min Walk 476 4.4 + 2.6 333 2.5 + 1.7 
Sitting or Rest N/A N/A 607 4.4 + 2.6 
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Table 18: Weekly and daily chores of households   
 
 Household 
Activity 
Cooking House 
Cleaning
Washing Running 
Errands 
Number of persons  793 485 422 477 369 
Average of 7 days 2.2 + 6.7 6 + 1 5.9 + 2.1 2.6 + 2.0 4.2 + 2.5 
      
Number of persons  494 452 483 385 
Average of 24 hours  1.8 + 1.4 4.3 + 9.7 7.6 + 1 14 + 22 
 
3.1.3 Part C: Anthropometry Section of Questionnaire 
Anthropometry section included measurements of weight, height, waist and hip 
circumference. It contained 18 variables. Collected anthropometric data included 
measurements of weight, height, waist and hip circumference. Participants were 
asked to wear light clothing and take off their shoes during anthropometry 
measurements. Height was measured to the nearest cm and weight to the nearest 
0.1 Kg. Weight was taken with a standardized scale and height with a standardized 
measuring stick. Waist circumference was measured as the mid point between the 
iliac crest and the lower margin of the ribs. Blood pressure was take by a medical 
student or doctor at least twice with 20 minute intervals, after ensuring that at least 30 
minutes had passed since tea or tobacco were last consumed. A third BP 
measurement was taken if one or both of the first two readings were above the cut-
offs for a diagnosis of hypertension.  
Table 19: Mean Anthropometry Measurements 
 n Mean 
Mid arm Circumference in cms 802 44.2 + 47.7 
Pulse (Beats per minute)   
1st reading  790 80 + 12.5 
 2nd reading 734 79.8 + 13.9 
 3rd reading 133 75.4 + 20.3 
Systolic Blood Pressure (mmHg)   
1st reading  787 119.7 + 25.3 
2nd reading 743 127.1 + 50.1 
3rd reading 136 126.8 + 19.1 
Diastolic Blood Pressure (mmHg)   
1st reading  787 87 + 21.4 
2nd reading 742 81.5 + 12.6 
3rd reading 138 81.2 + 14.3 
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Table 20: Categorical variables of Anthropometry   
 
Variable n ( 867) % mean Std. Dev.
Height (cm)   156.9 9.2 
Weight (kg)   60.6 15.9 
Hip circumference (cm)   95.4 14.0 
Waist circumference (cm)   86.1 15.5 
BMI 
Under weight (< 18) 
Normal (18 – 22.9) 
Over weight (23 - 25) 
Obese  (> 25) 
 
102 
251 
112 
402 
 
11.8 
28.9 
12.9 
46.3 
  
Waist Hip Ratio 
Normal (≤ 0.90) 
High (>0.90) 
 
320 
547 
 
 
63.1 
  
Systolic Blood Pressure   124. 22.6 
Diastolic Blood Pressure   81.3 32.3 
High Blood Pressure on BP readings 
≤ 130/85 mmHg  
> 130/85 mmHg 
 
681 
186 
 
 
21.4 
  
New & Previous Case of  hypertension 425 49.0   
 
At the end of each household visit, all persons who participated in the study were 
asked to undertake an 8 hour fasting for blood tests (fasting blood glucose, insulin 
levels and lipid profile) that was collected at home on Saturday and Sunday 
mornings. They were also provided a urine collection bottle and asked to collect a 
mid-stream urine specimen for tests (proteinuria and microalbuminuria) on the 
morning that their blood tests were due. 
A total of 867 gave consent to participate in the study. Only 363 persons gave blood 
samples out of these 867 adults having a response rate of 42% for blood collection.  
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Table 21: Means of anthropometric and biochemical parameters of subjects 
  Male 
Mean ± SD 
Female 
Mean ± SD 
Total 
Mean ± SD 
Age (years) 45.1± 15.7 38.8 ±12.8 40.8 ± 14.1 
BMI(kg/m2) 23.9 ± 7.2 26.0 ± 7.1 25.4 ± 7.2 
Waist  hip ratio 0.94 ± 0.11 0.91 ± 0.16 0.92 ± 0.15 
Waist circumference (cm) 89.5 ±16.0 87.8 ± 15.8 88.4 ± 15.8 
Systolic Blood Pressure (mmHg) 127.4 ± 18.6 124.3 ± 19.6 125.2 ± 19.3 
Diastolic Blood Pressure (mmHg) 84.3 ± 11.8 79.9 ±13.7 81.2 ± 13.3 
Fasting Plasma Glucose (mg/dl) 86.7 ± 21.7 86.6 ± 23.2 86.6 ± 22.7 
Cholesterol (mg/dl) 175.9 ± 42.6 180.7 ± 44.6 179.2 ± 43.9 
Triglycerides (mg/dl) 158.9 ± 105.2 135.2 ± 70.2 142.6 ± 83.3 
LDL (mg/dl) 110.7 ± 28.8 116.2 ± 33.0 114.5 ± 31.8 
HDL (mg/dl) 37.1 ± 10.4 43.2 ± 12.4 41.3 ± 12.2 
Insulin (mU/ml) 7.6 ± 2.7 8.3 ± 4.5 8.0 ± 4.0 
Urinary Microalbuminuria (mg/dl) 12.9 ± 12.4 14.9 ± 20.6 14.3 ± 18.3 
 
The biochemical analysis and assessment of risk factors based on these parameters 
were done on these 363 persons.  
Table 22: Cut-off values for biochemical variables  
Variable n (363) % mean Std. Dev.
Cholesterol   179.3 43.9 
≤ 200 mg/dl 
> 200 mg/dl 
219 
94 
70.0 
30.0 
  
Triglycerides   142.6 83.3 
≤ 150 mg/dl 
> 150 mg/dl 
210 
92 
69.5 
30.5 
  
Low Density Lipoprotein (LDL)   114.5 31.8 
≤ 130 mg/dl 
>130 mg/dl 
225 
88 
71.9 
28.1 
  
High Density Lipoprotein (HDL)   41.3 12.1 
≥ 40 & 50 mg/dl 
< 40 & 50 mg/dl 
96 
216 
30.8 
69.2 
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Fasting Blood Glucose    86.6 22.7 
≤ 100 mg/dl 
> 100 - ≤ 126 mg/dl  
> 126 mg/dl 
227 
15 
25 
85.0 
5.6 
9.4 
  
HOMA - IR   1.7 0.8 
> 25th Percentile 
< 75th Percentile 
64 
185 
25.7 
74.3 
  
 
3.1.4 Prevalence of abnormal glucose tolerance  
Prevalence of Diabetes was found to be 9.4% in our study. Of these 2.6% were 
known cases of diabetes while 6.8 % were new cases of Diabetes. Based on the 
Fasting criteria of IFG (FPG between 125 – 100 mg/dl) we identified 5.6% cases. 
Thus a total of 15% were found to have abnormal glucose tolerance. 
Figure 16: Prevalence of Diabetes and IFG 
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Figure 17: Age Distribution of Prevalence of glucose tolerance 
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We observed that as age advanced the number of Diabetes and IFG cases also 
increased. This was also evident by plotting Error Bar which showed that Diabetes 
and IFG subjects had a higher mean age and range compared to normal subjects.  
Figure 18: Error Bar of Glucose Tolerance with Age 
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3.1.5 Distribution of cardiovascular disease and its risk factors  
We identified 20 cases of cardiovascular disease out of 363 persons on the basis of 
self reporting of CVD showing a prevalence of 5.5%. Risk of CVD was 3 times [OR 
3.07; 95% CI (1.08-8.73)] in subjects with hypertension compared to non 
hypertensive subjects. Those having a waist hip ratio more than 0.90 had 3 times 
more risk of CVD compared to those with normal WHR [OR 3.08; 95% CI (0.88-
10.87)]. Smokers had twice risk of CVD compared to non smokers [OR 1.93; 95% CI 
(0.70-5.26)]. Diabetics had nearly two times risk of CVD compared to non diabetics 
[OR 1.79; 95% CI (0.38-8.28)],  
Table 23: Risk Factors of CVD 
Variable CVD 
n =20 
Normal 
n = 342 
OR      (95% CI) 
Age Mean 49.6 
SD (±12.4) 
Mean 40.4 
SD  (±14.1) 
4.97    (1.63-15.38)
Hypertension (%) 73.7 47.7 3.07     (1.08-8.73) 
High Waist Hip Ratio (%) 78.9 61.1 3.08     (0.88-10.87)
Family History for CAD (%) 13.3 18.8 0.66    (0.14-3.07) 
Current Smoker (%) 31.6 19.3 1.93     (0.70-5.26) 
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Variable CVD 
n =20 
Normal 
n = 342 
OR      (95% CI) 
BMI (> 23 kg/m2) (%) 55.6 59.5 0.85     (0.33-2.21) 
Diabetes (%) 20.0 8.4 1.79      (0.38-8.28)
3.1.6 Descriptive analysis of persons taking blood tests  
Around 363 persons gave blood samples and details of their descriptive analysis are 
given in table 24. 
Table 24: Age and Gender distribution of variables in subjects of blood tests  
 Age 25 -34 35 - 44 45 -54 55 -64 > 65 Total p value 
Male 
Female 
Overall 
n=37 
n=107 
(n=144) 
n=30 
n=68 
(n=98) 
n=15 
n=31 
(n=46) 
n=18 
n=28 
(n=46) 
n=17 
n=12 
(n=29) 
n=117 
n=246 
(n=363) 
 
Diabetes (%)       
Male 
Female 
Overall 
4.8 
2.5 
3.0 
0.0 
8.9 
6.2 
18.2 
13.6 
15.2 
0.0 
26.3 
15.6 
30.0 
36.4 
33.3 
7.5 
10.2 
9.4 
0.014 
0.001 
0.000 
IFG (%)        
Male 
Female 
Overall 
0.0 
2.5 
2.0 
0.0 
7.1 
4.9 
9.1 
4.5 
6.1 
15.4 
15.8 
15.6 
25.0 
9.1 
9.5 
5.0 
5.9 
5.6 
0.014 
0.001 
0.000 
HTN (>130/85 mmHg) (%)      
Male 
Female 
Overall 
40.5 
26.2 
29.9 
53.3 
54.4 
54.1 
60.0 
71.0 
67.4 
50.0 
78.6 
67.4 
64.7 
75.0 
69.0 
60.0 
48.0 
49.0 
0.480 
0.000 
0.000 
WHR > 0.90 (%)       
Male 
Female 
Overall 
45.9 
49.1 
48.3 
66.7 
70.1 
69.1 
69.2 
77.4 
75.0 
72.2 
82.1 
78.3 
75.0 
75.0 
75.0 
62.3 
63.5 
63.1 
0.160 
0.001 
0.000 
OW (BMI 23-25 kg/m2) (%)      
Male 
Female 
Overall 
8.1 
15.0 
13.2 
16.7 
7.6 
10.4 
16.7 
6.5 
9.3 
35.3 
7.1 
17.8 
31.3 
0.0 
17.9 
18.8 
10.2 
12.9 
0.080 
0.066 
0.136 
Obese (BMI > 25 kg/m2) (%)      
Male 
Female 
Overall 
43.2 
39.3 
40.3 
40.0 
60.6 
54.2 
33.3 
71.0 
60.5 
17.6 
67.9 
48.9 
12.5 
41.7 
25.0 
33.0 
52.5 
46.3 
0.080 
0.066 
0.136 
Cholesterol > 200 mg/dl (%)     
Male 
Female 
Overall 
20.7 
19.8 
20.0 
37.5 
34.5 
35.4 
35.7 
40.7 
39.0 
18.8 
53.8 
40.5 
21.4 
41.7 
30.8 
26.8 
31.5 
30.0 
0.516 
0.007 
0.028 
Triglycerides > 150 mg/dl (%)     
Male 
Female 
Overall 
44.4 
13.3 
20.5 
39.1 
37.7 
38.2 
35.7 
33.3 
34.1 
31.3 
46.2 
40.5 
28.6 
33.3 
30.8 
37.2 
27.4 
30.5 
0.850 
0.002 
0.043 
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LDL > 130 mg/dl (%)      
Male 
Female 
Overall 
27.6 
19.8 
21.6 
20.8 
29.1 
26.6 
42.9 
37.0 
39.0 
18.8 
53.8 
40.5 
21.4 
33.3 
26.9 
25.8 
29.2 
28.1 
0.550 
0.013 
0.080 
HDL < 40 & 50 mg/dl (%)      
Male 
Female 
Overall 
69.0 
65.6 
66.4 
60.9 
76.4 
71.8 
57.1 
66.7 
63.4 
62.5 
84.6 
76.2 
78.6 
66.7 
73.1 
65.6 
70.8 
69.2 
0.750 
0.309 
0.645 
Proteinuria (%)       
Male 
Female 
Overall 
3.7 
2.5 
2.8 
0.0 
6.3 
4.1 
0.0 
0.0 
0.0 
0.0 
4.3 
2.7 
0.0 
10.0 
4.5 
1.1 
3.9 
2.9 
0.660 
0.561 
0.821 
Micral (%)       
Male 
Female 
Overall 
3.7 
6.3 
5.7 
0.0 
8.5 
5.5 
0.0 
4.8 
3.0 
0.0 
8.7 
5.4 
0.0 
10.0 
4.5 
1.1 
7.2 
5.2 
0.660 
0.964 
0.983 
Tobacco Consumption (%)      
Male 
Female 
Overall 
32.4 
11.2 
16.7 
40.0 
16.2 
23.5 
33.3 
9.7 
17.4 
38.9 
17.9 
26.1 
23.5 
8.3 
17.2 
34.2 
13.0 
19.8 
0.820 
0.730 
0.533 
Family History of Heart Disease (%)    
Male 
Female 
Overall 
7.7 
19.7 
17.6 
15.0 
33.3 
27.7 
44.4 
0.0 
14.8 
0.0 
18.8 
12.0 
0.0 
0.0 
0.0 
13.3 
20.4 
18.4 
0.030 
0.026 
0.081 
Physical Activity (%)      
Male 
Female 
Overall 
83.3 
55.8 
60.9 
93.8 
54.1 
66.0 
57.1 
64.7 
62.5 
87.5 
61.5 
71.4 
44.4 
50.0 
46.7 
76.9 
56.8 
62.7 
0.037 
0.938 
0.614 
3.1.7 Prevalence of Metabolic syndrome – Different Definitions 
Metabolic syndrome was assessed by five different definitions as shown in Table 25. 
Age and gender specific prevalence of metabolic syndrome by different definitions 
was seen in our sample. 
Highest prevalence was observed by modified ATP III and lowest prevalence by 
WHO definition. Age and gender specific prevalence of metabolic syndrome was also 
calculated in Table25. The prevalence of metabolic syndrome increases with 
increasing age in both males and females. Significant differences in the prevalence 
with respect to age groups by all definitions were found in females only ( p values 
<0.05).   
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Table 25: Age & gender specific prevalence of metabolic syndrome by  
different definitions 
 
Age 
group 
n WHO 
% 
EGIR 
% 
AACE 
% 
ATP III 
% 
IDF 
% 
Overall 363 7.4 15.2 16.9 49 34.8 
Male       
25 - 34 37 0.0 8.1 16.2 54.1 31.3 
35 - 44 30 0.0 13.3 23.3 56.7 21.4 
45 - 54 15 20.0 13.3 26.7 53.3 46.7 
55 - 64 18 0.0 22.2 22.2 55.6 25.0 
> 65 17 11.8 17.6 17.6 58.8 43.8 
Total 117 4.3 13.7 20.5 55.6 31.8 
*Female       
25 - 34 107 1.9 15.9 2.8 27.1 14.9 
35 - 44 68 7.4 17.6 20.6 51.5 37.3 
45 - 54 31 12.9 19.4 22.6 58.1 60.0 
55 - 64 28 25.0 10.7 46.4 78.6 71.4 
> 65 12 33.3 8.3 25.0 75.0 66.7 
Total 246 8.9 15.9 16.3 45.9 36.1 
* p value <0.05 for WHO, ATP III, AACE and IDF 
 
Table 26 gives the prevalence of different components among those who classified 
as having metabolic syndrome according to five different definitions. All of the 
subjects have increased Waist circumference as defined by EGIR and IDF 
definitions. The prevalence of high blood pressure was 86.2% by ATP III, 82.1% by 
IDF, 78.2% by AACE, 50% by WHO and 47.6% by EGIR. Prevalence of high 
triglycerides levels was 59.7% by ATP III and 41.9% by EGIR. Prevalence of low HDL 
levels was 93.1% by AACE which is highest and 75.6% by WHO which is lowest. 
Microalbuminurea was 42.2% by WHO definition.  
Table 26: Prevalence of components of the metabolic syndrome  
 WHO 
n(%) 
 EGIR 
n(%) 
ATP III 
n(%) 
AACE 
n(%) 
IDF 
n(%) 
Waist  hip ratio 43(95.6) - - - - 
Waist Circumf.   32(100.0) 63(81.8)  100(100.0)
High BP (mmHg) 16(50.0) 10(47.6) 56(86.2) 68(78.2) 64(82.1) 
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High FPG (mg/dl) 22(48.9) 2(8.3) 16(26.2) 17(19.1) 27(33.8) 
High Trigly. (mg/dl) 21(50.0) 13(41.9) 53(69.7) 79(68.1) 59(60.2) 
Low HDL (mg/dl) 31(75.6) 25(80.6) 69(90.8) 108(93.1) 85(86.7) 
*HOMA(>2) 35(81.4) - - - - 
Micral (>20 mg/dl) 14(42.2) - - - - 
*Homeostasis Model Assessment; All p values <0.001 
3.1.8 Risk of IFG and CVD according to metabolic syndrome definitions 
 
The following odds ratio were observed when IFG and CVD risk was assessed by 
using the different Metabolic Syndrome definitions. 
Table 27: Risk of IFG  
Metabolic Syndrome  IFG (n =15) Normal (n=227) OR      (95% CI) 
    
WHO 53.3 0.0 33.43 (16.11 – 69.34) 
EGIR 53.3 15.9 6.06 (2.06 – 17.77) 
AACE 66.7 13.7 12.65 (4.05 – 39.48) 
ATP III 73.3 26.4 7.65 (2.35 – 24.95) 
IDF 73.3 26.4 7.65 (2.35 – 24.95) 
 
Table 28: Risk of CVD 
Metabolic Syndrome  CVD (n =20) Normal (n=342) OR      (95% CI) 
    
WHO 15.0 3.2 5.32 (1.36 – 20.89) 
EGIR 15.0 15.2 0.98 (0.28 – 3.49) 
AACE 30.0 16.9 2.11 (0.77 – 5.71) 
ATP III 70.0 47.8 2.55 (0.96 – 6.78) 
IDF 55.0 33.5 2.42 (0.97 – 6.02) 
3.1.9 Insulin Levels  
The insulin levels of 320 subjects was available for analysis while 249 persons had 
fasting insulin and fasting glucose levels both available. HOMA-IR was calculated 
and means and percentiles of Insulin and HOMA-IR defined.  
Table 29: Total Mean Values of Insulin Levels and HOMA-IR 
 
Insulin Levels HOMA - IR 
N Mean + SD N Mean + SD 
320 8.09 + 4.02 249 1.65 +0.85 
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Figure 19: Mean Values of HOMA-IR according to Age 
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Figure 20: Percentiles of Insulin and HOMA-IR 
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Discussion 
We are in the midst of a twin epidemic of Diabetes and cardiovascular disease which 
seems to be driven by the metabolic syndrome and the presence of the associated 
correlates in the metabolic syndrome confers a manifold increase in the risk for T2DM 
and CVD (56). Thus it is not only a medical, but also a socio-economic need to take 
all steps to try and prevent the ravages which can be caused by T2DM and CVD (2). 
The objective of the study was to determine the prevalence of metabolic syndrome in 
a sample of adults aged 25 years and above from an urban population of Karachi.  
 
4.1 Methodological consideration 
4.1.1 Study design 
Descriptive studies use routinely collected data which has not been specifically 
collected for the study during the time of collection of data. A cross-sectional 
(prevalence) survey is a descriptive study which collects data in a planned way from 
a defined population at a certain specific period of time. These data are then 
examined in relation to the presence or absence of the disease under investigation or 
its severity with a view to test hypothesis and look into associations between various 
factors. 
We planned such a cross-sectional survey in Lyari to establish epidemiological data 
on metabolic syndrome. Since such type of study is very time and resource intensive, 
this data is part of a larger collaborative study between Diabetic Association of 
Pakistan, Baqai Institute of Diabetology and Endocrinology, Interactive research and 
Development Organisation and a local area NGO – Lyari Community Development 
Project. The University of Oslo was involved from the start in this study in an advisory 
capacity. Since I was part of that project as lab field supervisor I have used data from 
that study. 
 
4.1.2 Selection of Survey Area 
 
Lyari was chosen as it is one of the oldest and densely populated part of Karachi city. 
Its residents form an extremely diverse community, representing almost every cultural 
and ethnic group found in Pakistan. There is similarly a wide spectrum of 
socioeconomic groups present here. 
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Lyari Town Geographical Information System (LTGIS) was used to define the 
geopolitical boundaries and population density of Lyari Town. The objective of 
developing the Lyari Town GIS was to lay the infrastructure for longitudinal follow-up 
studies of households to assess indicators that may be of interest to researchers, 
including determining the community-based prevalence of chronic diseases among 
adults as was done by our group.  
 
4.1.3 Sampling technique  
 
It is usually unnecessary to study the whole population in order to obtain useful and 
valid information about that population. The investigation of a smaller sample has 
some advantages such as reduced number of subjects who have to be interviewed, 
examined or investigated. It provides highly detailed information on smaller numbers. 
If a sample is used, it is essential to ensure that the subjects included in the sample 
are representative of the population being investigated. To ensure the representative 
ness commonly used technique is simple random sampling.  
In this sampling technique each subject in the parent population has an equal chance 
of being selected. One way of obtaining a random sample is to give each subject a 
number and than to use a computer generated table of random numbers to decide 
which subjects should be included. This is the method we used to select the 500 
households for our study by LTGIS. 
 
4.1.4 Sample size 
 
We assumed that the lower limit prevalence of T2DM to be 11% in this population.  
The size of the population from which the study sample was to be selected (persons 
25 years and older in Lyari Town) was 244,000, the worst acceptable result would be 
±1.5% from the true population value. Thus our study would require a sample of at 
least 713 individuals to have 80% power to detect the true population value.  
In the field we were able to interview more than the required sample size (n = 867) 
but people’s reluctance to have the blood tests left us with less than the desired 
sample size (n = 363) at the end of the study which gave us 40 – 45% power to 
predict true population value. However since the prevalence of metabolic syndrome is 
higher (between 20 -25%) compared with diabetes in south Asian population the 
sample size enabled us to analysis and interpret the results. 
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4.1.5 Response of the participants and data collection 
 
We depended on the information provided to us by the participants. In our survey the 
information about personal medical history and family history of disease was 
dependent on participant’s reply as no record of previous medical history or data on 
socioeconomic status or diet and activity record etc. is available for verification of the 
answer made by them. Hence we chose to interview the participants and rely on the 
information given by them. 
 
4.2 Methodological discussion 
A number of problems may arise in the design related to cross-sectional surveys and 
other studies which may invalidate the results unless they are handled properly. Even 
though this methodology was examined to focus on objectives, some questions on its 
strength and limitation can be raised. 
4.2.1 Strength of the study 
 
Lyari Town Geographical Information System was made to define the geopolitical 
boundaries and population density of Lyari Town. This was done by dynamically 
linking the national census database to a purpose built geographical information 
system (GIS).  A year-long, detailed physical survey of Lyari Town was undertaken 
using available plot maps, most of which were over 20 years old. Although these plot 
maps required extensive and careful updating, the final results of the physical survey 
were impressive; all household structures were given a unique identification number, 
along with all health, education and other civic facilities available to its residents. The 
edited plot maps were then newly traced, with the unique number ascribed to each 
household clearly visible and commercial and civic service clearly high-lighted. The 
new maps were finally digitized using a geo-referenced satellite image of Lyari town 
at 1 meter resolution. We have already generated a computerized random sample of 
500 households from among the 85,520 households households in Lyari Town. There 
were 11 union councils or subdivisions of Lyari Town where the samples were taken 
from ensuring that each union council had equal opportunity to be represented in the 
sample selection.  
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We expected approximately 1000 adult men and women 25 years and above in the 
500 households in Lyari. If members of a household that had been selected refused 
to consent to household interviews, we knocked on the third door to the right of that 
house (while standing facing the door of the original house) and seeked consent 
there. If we were refused again, we knocked on the next consecutive door to the right 
and repeated this process until we had enrolled a household from the neighbourhood. 
Individual members within households also reserve the right to refuse participation in 
the study. Assuming a 10% refusal rate (by members within the household at the time 
of interview) and another 10% refusal rate by those who decline to provide consent 
for a blood test, we expected at least 810 individuals to participate in this study. 
 
4.2.2 Limitations of the study 
4.2.2.1 Selection Bias 
Lyari was chosen as it is one of the oldest and most densely populated part of 
Karachi city. The rationale of choosing this area was that Its residents form a diverse 
community representing every major ethnic group found in Pakistan. There is 
similarly a wide spectrum of socioeconomic groups in the area which could possibly 
be representative of the general population. However this may not be enough to be 
representative for the whole of Pakistani population.  
By using computerized random selection of households by GIS we hope to minimize 
the selection bias. As the survey was done on weekdays it included a 
disproportionate greater number of females compared to males as the men went to 
work on weekdays and even some on weekends too.  
4.2.2.2 Recall and reporting Bias 
Subjective data collection in a survey by interview may pose some biases from recall 
problems. In the answer regarding positive family history of disease we encountered 
some unknown answers in the participants. Similarly such a problem came during 
reporting of dietary recall.  
Reporting bias can also arise from the standpoint of local cultural context. For 
example when the field team inquired about household income they noticed 
underreporting of income.  
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4.2.2.3 Response Bias 
Although 867 adults consented and were interviewed in our survey; only 363 
individuals gave blood samples in our study. Response rate was 42%. There could 
be a response bias in our study with subjects with a particular trend coming more for 
the blood test causing a selection bias also. To assess this we compared the two 
groups for compatibility and found that there were 27% males in the 867 sample 
compared to 32% in the 363 sample. The age, BMI, WHR, and systolic (SBP) and 
diastolic (DBP) blood pressure was also considerably similar in both the groups (Age 
= 40.7 vs. 40.8 years, BMI = 24.7 vs. 25.4 Kg/m2, WHR = 0.91 vs. 0.92 cm, SBP = 
125 vs. 125 mmHg and DBP= 81 vs. 81 mmHg in the 867 vs. 363 sample).  
Since most of the survey form was in as a structured interview questionnaire and 
subject to response by participants, if a question was not answered a variable would 
be missing in the final analysis. As regards the anthropometry measurements a 2 day 
certification course was arranged for the field team for measuring height, weight and 
blood pressure at the National Institute of Cardiovascular Diseases. Therefore all 
data was recorded by certified personnel.  
 4.2.2.4 External validity for generalization 
In terms of generalization or external validity the findings of this study reflected the 
scenario of urban Population. Lyari was chosen as it is the oldest and most densely 
populated part of Karachi city. Its residents form a diverse community representing 
every ethnic group found in Pakistan. The sex ratio is similar as for the country 
(male/female ratio of 1.034 males for lyari vs.1.045 males for the country). The mean 
age for males in lyari was 23.5 vs. 20.7 years for the country while for females it was 
24.5 in lyari vs. 21 years for the country; suggesting similar age and gender 
distribution as mentioned above for both populations. There is also similarity in the 
socioeconomic status in lyari and the country with 29% earning less than Pak 
Rs.3000 in lyari vs. 24% of the population living below the poverty line as defined 
earlier. Given this we believe that the findings of the study should have a fair 
representation for the general population. However the sample is too small to be 
statistically representative for the Pakistani population as a whole and thus the results 
should be interpretated with caution.  
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4.2.2.5 Reliability 
Blood pressure was taken by a medical student or doctor at least twice with 20 
minute intervals to ensure the reliability of the measurements. A third BP 
measurement was taken if one or both of the first two readings were above the 
cutoffs for a diagnosis of hypertension.  
4.3 Discussion on the findings of the study 
4.3.1 Socio-demography of the Sample   
The life expectancy is 62.7 years for males and 64.8 years for females in the country 
while we see in table 13 that the mean age at death of father (males) was 62.5 years 
while for mothers (females) is 59.7 years for lyari. This and other similarities as 
mentioned in external validity for generalization may suggest that this could be used 
as a representative sample for Pakistan.  
4.3.2 Prevalence of Abnormal Glucose Tolerance  
Prevalence of Diabetes was found to be 9.4%, with overall abnormal glucose control 
of 15% in our study. The national survey conducted by the Diabetic Association of 
Pakistan (DAP) in collaboration with the World Health Organization (WHO) during the 
1990s reported 11% prevalence of T2DM, with overall abnormal glucose control of 
22% (99–101). Conducted in urban and rural areas in the four provinces (NWFP, 
Balochistan, Punjab and Sindh), the national survey used WHO guidelines for the 
diagnosis of T2DM and impaired glucose tolerance (IGT) in over 5,600 persons 25 
years and above while we used only the fasting criteria. Probably doing OGTT might 
have yielded a higher prevalence of abnormal glucose tolerance with more cases of 
IGT compared to 5.6% of IFG. A relative higher prevalence of diabetes was observed 
in the 45–54 years age groups compared to IFG while the mean age was highest in 
diabetes followed by IFG and than normal population as shown in figure 17 and 18. 
Nearly 72% of the subjects did not know they had diabetes while nearly half of the 
subjects did not know in national survey (99-101).  
4.3.3 Risk factors for cardiovascular disease  
Although 18% reported chest discomfort in our study the prevalence of CVD was 
assessed to be 5.5% on the basis of self reporting of CVD. Two hospital based 
studies in Lahore and Sheikhupura concluded that the prevalence of symptomatic 
IHD was about 4% and 6% respectively (102).  
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4.3.4 Prevalence of Metabolic syndrome – Different Definitions  
Our data showed that the prevalence of metabolic syndrome ranged from 7.4 – 49% 
according to the different definitions used. The EGIR and AACE definitions did not 
include diabetes while ATP III, WHO and modified IDF definitions included diabetes 
and IGT. The EGIR suggested fasting hyperinsulinemia (upper 25th percentile) as the 
necessary component of metabolic syndrome. Since WHO and EGIR had a two 
stage screening process for subjects; fewer individuals qualified for the metabolic 
syndrome by these definitions. 
The prevalence of Metabolic Syndrome according to WHO criteria was low as 
compared to the other definitions, probably due to the mandatory inclusion of 
abnormal glucose tolerance cases. Probably due to this few persons qualified for the 
metabolic syndrome. High percentages of individuals were classified as having 
Metabolic Syndrome by modified ATP III and IDF criteria for Asians. The prevalence 
of metabolic syndrome also increases with advancing age. These findings are 
consistent with other studies [108-113].  
When stratified with respect to gender the prevalence was twice in females compared 
to males by WHO definition (4.3% for males; 8.9% for females). It was slightly higher 
in females by EGIR definition (13.7% for males and 15.9% for females) and by IDF 
definition (31.8% for males and 36.1% for females). It was higher in males by AACE 
definition (20.5% for males; 16.3% for females) and also by modified ATP III (55.6% 
for males; 45.9% for females).  
In Asians, the risk of diabetes and cardiovascular diseases occurs at lower levels of 
BMI, waist hip ratio and waist circumference compared to Caucasians. Taking this in 
consideration new cutoff values for Asian Indians have been defined [13,113].  Using 
these cutoffs for waist circumference and waist hip ratio the prevalence by ATP III 
was found to be 49% in our study. These observations using the modified ATP III 
were similar to findings from other studies done in the region showing prevalence 
ranging from 35.2% to 41% [113 - 114].  
The IDF definition also takes into consideration the new cut offs for Asians. The IDF 
definition assigned different cutoff of central obesity as defined by waist 
circumference for various ethnic groups to allow better comparison. A lower threshold 
for fasting plasma glucose in order to detect IGT was also suggested for modified 
ATP III and IDF.  
Muhammad Zafar 
 
79
Compared to our study which showed a prevalence of 34.8% of the metabolic 
syndrome, the prevalence was 26% according to the IDF definition in the Chennai 
Urban Rural Epidemiology Study done in India (115). This study showed a 
prevalence of 49% and 7.4% of the metabolic syndrome in an urban Pakistani 
population according to the modified ATP III and WHO definition. While other hospital 
based studies have showed a prevalence of 44% and 46% of the metabolic using 
ATP III and WHO (diabetic subjects only) definition respectively; this is the first 
community based study to show the prevalence of metabolic syndrome in our local 
population (104, 105).  
Our investigation was a preliminary study to investigate and explore different 
definitions of metabolic syndrome in our adult population who along with the other 
Asian ethnic groups, have different anthropometric characteristics in comparison with 
Caucasians. Metabolic abnormalities are present at a lower waist circumference in 
South Asians compared to Caucasians suggesting that modified ATP III criteria might 
be better at estimating the prevalence of metabolic syndrome in South Asians. 
Although the prevalence of metabolic syndrome by using modified ATP III definition 
was higher than IDF definition (49% vs. 34.8%) the risk for IFG cases was 
significantly higher in IDF definition compared to ATP III (OR 7.65 vs. 2.25). The risk 
for CVD was almost the same by both the definitions (OR 2.42 vs. 2,55). 
Based on the observations of the present study and those from other investigators, it 
is suggested that inclusion of modified waist circumference and BMI cutoffs as done 
in the modified ATP III and IDF definition would probably help metabolic syndrome 
prediction of diabetes and CVD more precisely.  
The modified ATP III and IDF definition aims to address both clinical and research 
needs and represents a step towards facilitating international consensus.  
4.3.5 Prevalence of Components of the metabolic syndrome   
Each risk factor of metabolic syndrome has its own variability based on its regulation 
through both genetic and acquired factors. The different prevalence rates of the 
various components of the metabolic syndrome were probably due to the variability in 
the cutoff values used by the different definitions.  
The study also shows that there is greater prevalence of hypertension, obesity and 
low HDL in metabolic syndrome group by any definition. Thus the contributing causes 
of this syndrome are similar everywhere. There appears to be a very high prevalence 
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of low HDL cholesterol in our metabolic syndrome group ranging from 75.6% to 
93.1%. A similarly high prevalence of low HDL cholesterol in women was seen in an 
Indian study (111).  
4.3.5.1 Hypertension:  
Our study found that 49% of the subjects were hypertensive in the community. Out of 
these 27.6% were known hypertensives while 21.4% were newly diagnosed on the 
basis of blood pressure readings as shown in table 20.  
Another study done in Karachi found that more than 50% of the subjects were 
hypertensive but this was done in type 2 diabetic subjects (116). 
4.3.5.2 Obesity: 
Since there is increased cardiovascular risk among Asian people at a lower waist 
circumference compared to European populations, the World Health Organization 
(WHO) and the International Diabetes Federation (IDF) have adopted the definition of 
overweight and obesity in Asians as a BMI of 23 kg/m2 or above and 25 kg/m2 or 
above respectively, while central obesity was defined as a waist circumference of 90 
cm or above in men and 80 cm or above in women (117). 
In our study it was observed that 68% of women and 46% of men were obese 
according to the Asian cut off criteria for waist circumference. Similarly using BMI 
criteria for Asians in another study done in Hub we found 18% to be obese while 27% 
were found to be overweight (118). Analyzing the data of 8972 individuals of the 
National Health Survey of Pakistan it was found that a quarter of the population would 
be classified as overweight or obese on the basis of Indo-Asian-specific BMI cutoff 
values (119).Thus it seems that the obesity epidemic is affecting not only the affluent 
nations but the developing countries are also facing a similar threat and Pakistan also 
seems to be one of them. 
4.3.5.3 Dyslipidemia: 
Our study revealed that 30.5% of the people in the community were having 
high(>150mg/dl) triglyceride levels and 69.2% people were having low (< 40mg/dl for 
males and <50mg/dl for females) HDL levels. The characteristic lipid disorders seen 
in this syndrome are high triglycerides and low levels of HDL-cholesterol often with 
normal levels of LDL- cholesterol (120).  
Studying the association between biochemical parameters and obesity indicators in 
Pakistani children it was observed that those children who were in the uppermost 
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tertile of arm fat % had significantly higher total cholesterol, triglyceride and LDL-C 
levels (121). Thus the need to implement programmes to stop our children from 
becoming overweight so that they do not develop metabolic syndrome in the future. 
 
4.3.6 Defining Insulin Resistance according to Homa-IR 
4.3.6.1 Homeostasis model assessment (HOMA) 
HOMA was developed by Matthews as a method for estimating insulin sensitivity 
from fasting serum insulin and fasting plasma glucose (122). The non-linearity of the 
model precludes an exact algebraic solution, but estimations are possible by using 
mathematical approximations: 
HOMA-B = Insulin (mU/ml) × 20/ glucose (mmol/l) - 3.5 
HOMA-R      =      Insulin      (mU/ml)        ×         glucose      (mmol/l)/22.5 
The model has been incorporated into a simple MS-DOS-based computer program 
that allows rapid and more accurate determinations of HOMA-B and HOMA-R (123).  
Low HOMA values indicate high insulin sensitivity, whereas high HOMA values 
indicate low insulin sensitivity.  
Matthews found HOMA ranges between 1.21 and 1.45 in normal subjects in his study 
while the mean values was between 1.12 to 1.94 in our subjects (122).  
The 75th percentile of HOMA-IR was used as a cut-off for insulin resistance and it 
was found to be HOMA-IR =1.94. 
A large number of epidemiological and clinical studies have firmly established 
consistent correlations between certain anthropometric and metabolic variables of 
insulin resistance. These variables include obesity, unfavourable body fat distribution, 
glucose intolerance or type2 diabetes, hyper-insulinemia, low levels of HDL , hyper-
triglyceridemia, high levels of LDL and hypertension (124). In our study it was seen 
that Homa – IR increases with age and some of the variables mentioned above may 
be affected by this association of insulin resistance with age as obesity, risk of 
diabetes and hypertension as well as dyslipidemia all increase with age.   
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Chapter 5. Conclusions, Recommendations and 
Future Research Implication 
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5.1 Conclusions 
 
In summary we conclude that the prevalence of the metabolic syndrome was found to 
be between 7.4% - 49% using the various definitions of metabolic syndrome. 
Using different definitions, prevalence of the metabolic syndrome has been reported 
consistently to range from 10% to 40% in most Asian countries..  
 
We focused on the ATP III and  IDF definitions as they provides a diagnostic tool 
which is suitable for use in populations around the world and established a list of 
potential additional criteria that could be included in epidemiological studies and other 
research into the metabolic syndrome. 
 
The prevalence of metabolic syndrome increases with advancing age for both males 
and females.  More than half of our study population does not do any sort of physical 
exercise and lead a sedentary lifestyle. Thus we find that the contributing causes of 
this syndrome are similar everywhere with obesity and sedentary lifestyle in the 
forerun.  
 
Unless preventive programs are properly designed and implemented, we will 
continue to treat the majority of the cases when they have reached the steeper 
extreme of the road; when many have already developed the complications of the 
metabolic syndrome in the form of diabetes and cardiovascular diseases. 
 
Based on the findings of this study we made the following recommendations 
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5.2 Recommendations 
 
1. The primary management goals of the metabolic syndrome are to reduce the 
risks of diabetes and cardiovascular diseases. The metabolic syndrome should 
be considered as a prime target for preventive medicine; as the emerging 
global epidemic of metabolic and vascular disease has significant implications 
for the development of population based health policies. 
 
2. Despite the challenges involved in day-to-day life, the non-pharmacological 
lifestyle modification approach to prevention of the metabolic syndrome is 
highly effective. This was observed in the Finnish Prevention Trial where none 
of the people who achieved at least four of the intervention goals developed 
diabetes during the observation period of 10 years. 
 
3. Need for a diabetes prevention and control program is particularly relevant in 
Pakistan as increased inherent predisposition, younger age of onset, lack of 
capacity to effectively treat the condition at the primary healthcare level and 
lack of access to healthcare system for possible complications makes a strong 
case for investment in diabetes prevention and control programmes. 
 
4. A large number of lifestyle-related risk factors are associated with the 
metabolic syndrome and diabetes. These include family history, smoking, 
physical inactivity, watching television, consuming fast foods and high-sugar 
drinks and low socio-economic status. To increase people’s awareness 
seminars and public events should be arranged to highlight the significant of a 
healthy lifestyle.  
 
5. WHO and IDF has made recommendations to governments worldwide for the 
development of nationwide surveillance and prevention programmes against 
non-communicable diseases, including diabetes. However, the combined 
efforts of communities, governments and advocacy groups are needed to 
translate this evidence into clinical practice. 
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5.3 Further research implication 
 
1. Metabolic Syndrome definitions have to be assessed for predicting future 
cases of IGT/IFG and diabetes in Asian populations. Thus a prospective study 
of 3 years duration needs to be initiated to follow subjects with and without the 
metabolic syndrome to observe how many become IGT/IFG or develop 
diabetes after 3 years. This will help to monitor disease trends and a further 2 
year follow up to observe how many of the IGT cases identified during this 
period progressed to diabetes with give a better understanding of the 
predictive value of the metabolic syndrome.  
 
2. In several randomized trials, drug intervention has shown to be less effective 
than therapeutic lifestyle interventions in the prevention of type 2 diabetes. We 
need to evaluate the efficacy of lifestyle modifications and drugs as a means of 
primary prevention in a population with similar environmental conditions and 
genetic propensity as the Pakistani population such as the recent Indian 
Diabetes Prevention Programme.  
 
3. Policy changes and community mobilization schemes need to be initiated. 
Lifestyle modification programmes with emphasis on increasing physical 
activity (30 minutes of brisk walking), adhering to a balanced diet (high in fibre 
and low in fat), and losing body weight has shown to reduce the risk of 
progression from impaired glucose tolerance to diabetes in up to 58% cases.  
 
4. The involvement of a multidisciplinary team to reach targets and improve 
adherence to treatment has also been shown to reduce death and disability by 
up to 70% in people with established diabetes.  
 
5. These programmes will aim to collect population based data, monitor disease 
trends and create an environment that will help in promoting healthy lifestyles 
through multi-sectoral and inter-disciplinary collaborations. 
Acknowledgement: 
We acknowledge the support of Merck Marker for lab tests. 
Muhammad Zafar 
 
86
 
References 
 
1. Zimmet, P. Globalization, coca-colonization and the chronic disease 
epidemic: can the doomsday scenario be averted? J. Intern. Med. 247, 
301–310 (2000). 
 
2. Zimmet, P. Alberti, K. G. M. M. Shaw, J. Global and societal implications of 
the diabetes epidemic. Nature. 2001 Dec 13;414(6865):782-7.  
 
3. Zimmet, P. Diabetes epidemiology as a tool to trigger diabetes research 
and care Diabetologia 42, 499–518 (1999). 
 
4.  Hennekens, G. & Buring, J. Epidemiology in Medicine (Little, Brown, 
Boston, 1987). 
 
5. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic 
syndrome: a global public health problem and a new definition. J 
Atheroscler Thromb 2005;12(6):295-300.  
 
6. King, H., Aubert, R. & Herman, W. Global burden of diabetes, 1995-2025. 
Prevalence, numerical estimates and projections. Diabetes Care 21, 1414–
1431 (1998).  
 
7. Diabetes Atlas, second edition, International Diabetes Federation, 2003. 
 
8. American Diabetes Association. Economic consequences of diabetes 
mellitus in the U.S. in 1997. Diabetes Care 21, 296–309 (1998). 
 
9. UKPDS Group. UK Prospective Diabetes Study 17: A nine-year update of a 
randomized, controlled trial on the effect of improved metabolic control on 
complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 
1996;124:136–45.  
 
10. Reaven, G. Role of insulin resistance in human disease. Diabetes 37, 
1595–1607 (1988).  
 
11. Robert C, Schlant R, and W. A., The Heart, arteries and veins,. 8th ed. Vol. 
1. 1994: McGraw Hill, New York. 1185 - 1205. 
 
12. Kumar V and B. K., Basic Pathology. 6th ed. 1997: W. B. Saunders 
company. 308 -339. 
 
13. Padmavati, S., Prevention of heart disease in India in the 21st century: 
need for a concerted effort. Indian Heart J, 2002. 54(1): p. 99-102. 
 
14. The World Health Report: Making a difference. 1999: World Health 
Organization, Geneva Switzerland. 
 
Muhammad Zafar 
 
87
15.  Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus 
Group. The metabolic syndrome- a new worldwide definition. Lancet 
2005;366:1059-62.  
 
16. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide 
definition. A Consensus Statement from the International Diabetes 
Federation. Diabet Med 2006 May;23(5):469-80. 
 
17. The metabolic syndrome, Diabetes Voice special issue, May 2006, 51. 
 
18. Yousuf, S., et al., Global burden of cardiovascular diseases: Part II: 
variations in cardiovascular disease by specific ethnic groups and 
geographic regions and prevention strategies. Circulation, 2001. 104(23): 
p. 2855-64. 
 
19. 1997 - 1999 World Health Statistics Annual. World Health Statistics, 2000. 
 
20. Murray, C.J. and A.D. Lopez, Mortality by cause for eight regions of the 
world: Global Burden of Disease Study. Lancet, 1997. 349(9061): p. 1269-
76. 
 
21. D., L.A., Assessing the burden of mortality from cardiovascular disease. 
World Health Stat Q., 1993. 46: p. 91-96. 
 
22. Reddy, K.S., Cardiovascular diseases in India. World Health Stat Q, 1993. 
46(2): p. 101-7. 
 
23. Gupta, R., et al., Prevalence of coronary heart disease and coronary risk 
factors in an urban population of Rajasthan. Indian Heart J, 1995. 47(4): p. 
331-8. 
 
24. Kutty, V.R., et al., Prevalence of coronary heart disease in the rural 
population of Thiruvananthapuram district, Kerala, India. Int J Cardiol, 
1993. 39(1): p. 59-70. 
 
25. Gupta, R., V.P. Gupta, and N.S. Ahluwalia, Educational status, coronary 
heart disease, and coronary risk factor prevalence in a rural population of 
India. BMJ, 1994. 309(6965): p. 1332-6. 
 
26. Singh, R.B. and M.A. Niaz, Coronary risk factors in Indians. Lancet, 1995. 
346(8977): p. 778-9. 
 
27. Murray, C.J. and A.D. Lopez, Regional patterns of disability-free life 
expectancy and disability-adjusted life expectancy: global Burden of 
Disease Study. Lancet, 1997. 349(9062): p. 1347-52. 
 
28. Reddy, KS. and Yusuf, S. Emerging Epidemic of Cardiovascular Disease in 
Developing Countries  Circulation, Feb 1998; 97: 596 - 601. 
 
Muhammad Zafar 
 
88
29. www.idf.org/metabolic_syndrome, website of the International Diabetes 
Federation. 
 
30. Stern M, Williams K, Gonzalez-Villalpando C et al. Does the metabolic 
syndrome improve identification of individuals at risk of type 2 diabetes 
and/or cardiovascular disease? Diabetes Care 2004;27(11):2676-81.  
 
31. Diabetes Atlas, third edition, International Diabetes Federation, 2006.  
 
32. Sattar N, Gaw A, Scherbakova O. Metabolic syndrome with and without 
creactive protein as a predictor of coronary heart disease and diabetes in 
the West of Scotland Coronary Prevention Study. Circulation 
2003;108:414-9  
 
33. Golden SH, Folsom AR, Coresh J et al. Risk factor grouping related to 
insulin resistance and their synergistic effects on subclinical 
atherosclerosis: the atherosclerosis risk in communities study. Diabetes 
2002;51:3069-76.  
 
34. Hu G, Qiao Q, Tuomilehto J et al for the DECODE Study Group. 
Prevalence of the metabolic syndrome and its relation to all-cause and 
cardiovascular mortality in nondiabetic European men and women. Arch 
Intern Med 2004;164:1066-76  
 
35. Kylin E. Studien uber das Hypertonie-Hyperglyka ‘mie-Hyperurika’ 
Miesyndrom. Zentralbl Inn Med 1923;44:105—27. 
 
36. Vague J. La differenciation sexuelle, facteur determinant des formes de 
l’obesite’. Presse Medl 1947;53:339—40.  
 
37. Vague J. The degree of masculine differentiation of obesities: a factor 
determining predisposition to diabetes, atherosclerosis, gout, and uric 
calculous disease. Am J Clin Nutr 1956;4:20—34.  
 
38. Vague J, Vague P, Jubelin J. A 35-year follow up of diabetogenic obesity. 
Int J Obes 1985;11(Suppl. 2):38.  
 
39. Avogaro P, Crepaldi G. Essential hyperlipidemia, obesity and diabetes. 
Diabetologia 1965;1:137.  
 
40. Camus J. Goutte, diabe´te, hyperlipe´mie: un trisyndrome me´tabolique. 
Rev Rheumatol 1966;33:10—4. 
 
41. Pyorala K. Relationship of glucose tolerance and plasma insulin to the 
incidence of coronary heart disease: results from two population studies in 
Finland. Diabetes Care 1979;2:131—41. 
 
42. Modan M, Halkin H, Almog S, EshkolA, ShefiM, Shitrit A, et al. 
Hyperinsulinemia. A link between hypertension, obesity, and glucose 
intolerance. J Clin Invest 1985;75:809—17.  
Muhammad Zafar 
 
89
 
43. Reaven G. Banting lecture. Role of insulin resistance in human disease. 
Diabetes 1988;37:1595—607. 
 
44. World Health Organization. Denition, diagnosis and classication of diabetes 
mellitus and its complications. Report of a WHO consultation; 1999. 
 
45. Balkau B, Charles M. Comment on the provisional report from the WHO 
consultation. European Group for the Study of Insulin Resistance (EGIR). 
Diabet Med 1999;16:442—3. 
 
46. Executive summary of the third report of the National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, Evaluation, And 
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 
JAMA 2001;285:2486—97. 
 
47. Einhorn D, Reaven G, Cobin R, Ford E, Ganda O, Handelsman Y, et al. 
American College of Endocrinology position statement on the insulin 
resistance syndrome. Endocr Pract 2003;9:237—52.  
 
48. International Diabetes Federation. The IDF consensus worldwide definition 
of the metabolic syndrome. Available at 
http://www.idf.org/webdata/docs/IDF_Metasyndrome_definition.pdf  
 
49.  Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B, et al. 
Diagnosis and management of the metabolic syndrome: an American Heart 
Association/National Heart, Lung, and Blood Institute scientific statement. 
Circulation 2005;112:2735—52. 
 
50. Ford ES: Risks for all-cause mortality, cardiovascular disease, and 
diabetes associated with the metabolic syndrome: a summary of the 
evidence. Diabetes Care 28:1769–1778, 2005. 
 
51. Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a 
critical appraisal: joint statement from the American Diabetes Association 
and the European Association for the Study of Diabetes. Diabetes Care 
28:2289–2304, 2005.  
 
52. Grundy SM: The metabolic syndrome still lives. Clin Chem 51:1352–1354, 
2005.  
 
53. Reaven G. The metabolic syndrome: requiescat in pace. Clin Chem 
2005;51:931—8.  
 
54. Wang J, Thornton J, Bari S, Williamson B, Gallagher D, Heymsfield S, et 
al. Comparisons of waist circumferences measured at 4 sites. Am J Clin 
Nutr 2003;77:379—84.  
 
Muhammad Zafar 
 
90
55. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 
Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 
2003;11:3160—7.  
 
56. International Diabetes Federation. Rationale for new IDF worldwide 
definition of metabolic Syndrome. Available at 
http://www.idf.org/webdata/docs/Metabolic_syndrome_rationale.pdf  
 
57. Eckel R, Grundy S, Zimmet P. The metabolic syndrome. Lancet 
2005;365:1415—28.  
 
58. Grundy SM. Metabolic syndrome: connecting and reconciling 
cardiovascular and diabetes worlds. J Am Coll Cardiol 2006;47:1093—100.  
 
59. Grundy S, Haffner S, Kunos G, Jensen M. Managing Cardiometabolic risk: 
will new approaches improve success? Available at 
http://www.medscape.com/viewprogram/5700_pnt  
 
60. Resnick HE, Strong Heart Study Investigators. Metabolic syndrome in 
American Indians. Diabetes Care 2002;25:1246–1247. 
 
61. Ilanne-Parikka P, Eriksson JG, Lindstrom J, Hamalainen H, Keinanen-
Kiukaanniemi S, Laako M, Louheranta A, Mannelin M, Rastas M, Salminen 
V, Aunola S, Sundvall J, Valle T, Lahtela J, Uusitupa M, Tuomilehto J, on 
behalf of the Finnish Diabetes Prevention Study Group. Prevalence of the 
metabolic syndrome and its components: findings from a Finnish general 
population sample and the Diabetes Prevention Study cohort. Diabetes 
Care 2004;27:2135–2140. 
 
 
62. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among 
US adults. JAMA 2002;287:356–359. 
 
63. Ford ES, Giles W, Mokdad A. Increasing prevalence of the metabolic 
syndrome among US adults. Diabetes Care 2004;27:2444–2449. 
 
64. Aguilar Salinas CA, Rojas R, Go´mez-Pe´rez FJ, Valles V, Rı´os-Torres 
JM, Franco A, Olaiz G, Rull JA, Sepulveda J. Analysis of the agreement 
between the World Health Organization criteria and the National 
Cholesterol Education Program-III definition of the metabolic syndrome: 
results from a population-based survey. Diabetes Care 2003;26:1635.  
 
65. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. 
Cardiovascular morbidity and mortality associated with the metabolic 
syndrome. Diabetes Care 2001;24:683—9.  
 
66. Lakka H, Laaksonen D, Lakka T, Niskanen L, Kumpusalo E,.Tuomilehto J, 
et al. The metabolic syndrome and total and cardiovascular disease 
mortality in middle-aged men. JAMA 2002;288:2709—16.  
 
Muhammad Zafar 
 
91
67. Alexander C, Landsman P, Teutsch S, Haffner S. Third National Health 
and Nutrition Examination Survey (NHANES III); National Cholesterol 
Education Program (NCEP), NCEP defined metabolic syndrome, diabetes, 
and prevalence of coronary heart disease among NHANES III participants 
age 50 years and older. Diabetes 2003;52:1210—4.  
 
68. de Simone G. State of the heart in the metabolic syndrome. Nutr Metab 
Cardiovasc Dis 2005;15:239—41. 
 
69. Malik S, Wong N, Franklin S, Kamath T, L’Italien G, Pio J, Rhys William G. 
Impact of the metabolic syndrome on mortality from coronary heart 
disease, cardiovascular disease and all causes in United States adults. 
Circulation 2004;110:1245–1250. 
 
70. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, 
D’Armiento M, D’Andrea F, Giugliano D. Effect of a Mediterranean style 
diet on endothelial dysfunction and markers of vascular inflammation in the 
metabolic syndrome. JAMA 2004;292:1440–1446. 
 
71. Yach D et al, The Global Burden of Chronic Disease, JAMA. 2004; 291: 
2616- 2622.  
 
72. Murray CLJ, Lopez AD. Global burden of disease, Harvard MA: Harvard 
School of Public Health 1996.  
 
73. Roglic G, King H, Diabetes in Asia, HKMJ 2000; 6: 10-11. 
 
74. Wilde S et al, Global Prevention of Diabetes Estimates for the year 2000 
and projections for 2030, Diabetic Care 2004; 27:1047-1054.  
 
75. Dhawan, J., Coronary artery disease in South Asians: An overview of risk 
factors and the insulin resistance syndrome. Coronary Artery Disease in 
South Asians: Epidemiology, Risk factors and Prevention., ed. K.V.V. Rao 
G H. 2001, New Delhi: Jaypee Brothers. 322. 
 
76. Jafar, TH et al, Ethnic differences and determinants of diabetes and central 
obesity among South Asians of Pakistan, Diabetic Medicine 2004; 21: 716-
723. 
 
77. King, H., Aubert, RE. and Herman, WH., Diab. Care, 1998, 21, 1414–1431. 
 
78. Reddy, KS. Cardiovascular diseases in the developing countries: 
dimensions, determinants, dynamics and directions for public health action.  
Public Health Nutrition, Volume 5, Special Issue 1a, February 2002, pp. 
231-237(7). 
 
79. Yousuf S, R.K., Stephan O, et al., Global burden of cardiovascular 
diseases. Part I: general considerations, the epidemiologic transition, risk 
factors, and impact of urbanization. Circulation, 2001. 104: p. 2746-2753. 
 
Muhammad Zafar 
 
92
80. Tai, ES., Lim, SC., Chew, SK., Tan, BY. and Tan, CE. Homeostasis model 
assessment in a population with mixed ethnicity: the 1992 Singapore 
National Health Survey. Diabetes Research and Clinical Practice, Volume 
49, Issues 2-3, August 2000, Pages 159-168. 
 
81. Snehalatha, C., Satyavani, S., Sivasankari, S., Vijay, V. and 
Ramachandran, A. Insulin secretion and action in different stages of 
glucose tolerance in Asian Indians. Diabetic Medicine 16 : 408 - 414, 1999.  
 
82. Reaven G. The metabolic syndrome or the insulin resistance syndrome? 
Different names, different concepts, and different goals. Endocrinol Metab 
Clin North Am 2004;33:283—303.  
 
83. Misra A and Vikram NK. Insulin resistance syndrome (metabolic syndrome) 
and Asian Indians. Current Science, Vol. 83, No. 12, 25 December 2002 
1483-1496.  
 
84. Ramchandran A, Snehalatha C, Latha E, Satyavani K, Vijay V. Clustering 
of Cardiovascular Risk factors in Urban Asian Indians. Diabetes Care 
1998;21:967-71. 
 
85. Pais P, Pogue J, Gerstein H et al. Risk factors for acute myocardial 
infarction in Indians: a case-control study. Lancet 1996;348:358-63. 
 
86. DeFronzo RA. and Ferrannini, E., Diab. Care, 1991, 14, 173–194. 
 
87. Chandalia, M., Abate, N., Garg, A., Stray-Gundersen, J. and Grundy, SM., 
J. Clin. Endocrinol. Metab., 1999, 84, 2329–2335. 
 
88. Dhawan, J., Bray, CL., Warburton, R., Gambhir, DS. and Morris, J.,  
 Br. Heart J., 1994, 72, 413–421. 
 
89. Laws, A., Jeppesen, JL., Maheux, PC., Schaaf, P., Chen, YD. and Reaven, 
GM., Arterioscler. Thromb., 1994, 14, 917–922. 
 
90. Misra, A., Chaudhary, D., Vikram, NK., Pandey, RM., Mittal, V., Rama 
Devi, J., Khanna, N., Sharma, R. and Peshin, S., Diab.Res. Clin. Pract., 
2002, 56, 73–75. 
 
91. Gopinath, N., Chadha, SL., Jain, P., Shekhawat, S. and Tandon, R.,  
 J. Assoc. Phys. India, 1994, 42, 212–215.  
 
92. Murray, CJL. and Lopez, AD., WHO, Geneva, 1994. 
 
93. McKeigue, PM., Miller, GJ. and Marmot, MG., J. Clin. Epidemiol., 1989, 42, 
597–609.  
 
94. Despres, JP., Lamarche, B., Mauriege, P., Cantin, B., Dagenais, GR., 
Moorjani, S. and Lupien, PH., N. Engl. J. Med., 1996, 334, 952–957. 
 
Muhammad Zafar 
 
93
95. McKeigue PM, Marmot MG. Mortality from coronary heart disease in Asian 
communities in London. BMJ 1988; 297: 903. 
 
96. McKeigue PM, Marmot MG, Syndercombe Court YD, Cottier DE, Rahman 
S, Riemersma RA. Diabetes, hyperinsulinaemia and coronary risk factors 
in Bangladeshis in East London. Br Heart J 1988; 60: 390–396. 
 
97. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin 
resistance with high diabetes prevalence and cardiovascular risk in South 
Asians. Lancet 1991; 337: 382–386. 
 
98. Stephen JC and Sattar N. Impact of ethnicity on metabolic disturbance, 
vascular dysfunction and atherothrombotic cardiovascular disease. 
Diabetes, Obesity and Metabolism, 7, 2005, 463–470. 
 
99. Shera AS, Rafique G, Khuwaja IA, Ara J, Baqai S, King H. Pakistan 
National Diabetes Survey: prevalence of glucose intolerance and 
associated factors in Shikarpur, Sindh province. Diabet Med 
1995;12(12):1116-21. 
 
100. Shera AS, Rafique G, Khwaja IA, Baqai S, Khan IA, King H, et al. 
Pakistan National Health Survey:prevalence of glucose intolerance and 
associated factors in North West Frontier Province (NWFP) ofPakistan. J 
Pak Med Assoc 1999; 49(9):206-11. 
 
101. Shera AS, Rafique G, Khawaja IA, Baqai I, King H. Pakistan National 
Diabetic Survey: prevalence of glucose intolerance and associated factors 
in Balochistan province. Diabetes Res Clin Pract 1999;44(1):49-58. 
 
102. Zia UV, A.A., Awais MB., Ischemic heart disease in the young population 
(35 years): A clinical profile. PJC, 1995. 6(4): p. 63-66. 
 
103. Yousuf S, R.K., Stephan O, et al., Global burden of cardiovascular 
diseases. Part I: general considerations, the epidemiologic transition, risk 
factors, and impact of urbanization. Circulation, 2001. 104: p. 2746-2753. 
 
104. Wierzbicki AS,Nishtar S,Lumb PJ, Lambert-Hammill M,Turner CN,Crook 
MA,Marber MS,Gill J. Metabolic syndrome and risk of coronary heart 
disease in a Pakistani cohort. Heart. 2005 Aug;91(8):1003-7. 
 
105. Ashraf SMS, Ziauddin F, Jahangeer U.  Metabolic Syndrome in Type-2 
Diabetes Mellitus Pak J Med Sci 2006, 22 (3) 295-299. 
 
106. Nishtar S, Shera S ,Diabetes prevention and control as a part of an 
integrated non-communicable disease strategy: the Pakistan approach, 
Practical Diabetes International 2006,  23(8):332 – 334. 
 
107. Nishtar S et al. Waist hip ratio and low HDL predict the risk of coronary 
artery disease in Pakistanis. curr Med Res Opin 2004;20(1):55-62. 
 
Muhammad Zafar 
 
94
108.  Wang JJ, Hu G, Miettinen HE, Tuomilehto J, The metabolic syndrome 
and incident diabetes: Asessment of four suggested definitions of the 
metabolic syndrome in a Chinese population with high post prandial 
glucose, Horm Metab Res 36(2004) 708-715. 
 
109. Moran MR, Vazquez BS, Violanie R, Romero FG, Metabolic syndrome 
Among children and adolescents aged 10-18 years, Diabetes Care 
27(2004) 2516-2517. 
 
110. Balkau B, Charles MA, Drivsholm T, Johnsen KB, Wareham N, Judkin 
JS, et al, Frequency of the WHO metabolic syndrome in European cohorts, 
and an alternative definition of an insulin resistance syndrome, Diabetes 
Care 28  5(2002) 364-76. 
 
111. Misra A, Wasir JS, Pandey RM,  An Evaluation of Candidate Definitions 
of the Metabolic Syndrome in Adult Asian Indians,  Diabetes Care 28(2005) 
398-403. 
 
112. World health organization, Physical Status: the use and interpretation of 
anthropometry, Report of a WHO expert committee, WHO Technical 
Report Series No. 854, Geneva, 1995.   
 
113. Ramachandarn A, Snehalatha C, Satyavani K, Sivasankari S,  
Vishwanathan V, Metabolic Syndrome in Urban Asian Indian Adults: A 
population study using modified ATP III criteria, Diabetes Res Clin Pract  
60(2003) 199-204. 
 
114. Jahan F, Qureshi R, Borhany T, Hamza HB. Metabolic syndrome: 
frequency and gender differences at an Out-Patient clinic. J Coll Physicians 
Surg Pak Jan 2007;17(1):32-5.  
 
115. Deepa M, Pradeepa R, Rema M, Mohan A, Deepa R, Shanthirani S, 
Mohan V. The Chennai Urban Rural Epidemiology Study (CURES)--study 
design and methodology (urban component) (CURES-I). J Assoc 
Physicians India. 2003 Sep;51:863-70. 
 
116. Basit A, Hydrie MZI, Hakeem R, Ahmedani MY and Masood Q. 
Frequency of chronic complications of type 2 diabetes JCPSP 2004 
February(14)2:79-83. 
 
117. Misra A, Insulin resistance syndrome (metabolic syndrome) and obesity 
in Asian Indians: evidence and implications.  Nutrition,2004,20(5): 482-491. 
 
118. Basit A, Hydrie MZI, Ahmed K, Hakeem R. Prevalence of diabetes, 
impaired fasting glucose and associated risk factors in a rural area of 
Baluchistan province according to new ADA criteria. J Pak Med Assoc Aug 
2002;52(8):357-60. 
 
Muhammad Zafar 
 
95
119. Tazeen H. Jafar, Chaturvedi N, Pappas G, Prevalence of overweight and 
obesity and their association with hypertension and diabetes mellitus in an 
Indo-Asian population CMAJ. 2006 ;175(9):1071-7. 
 
120. Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular 
disease: a reappraisal. J Clin Endocrinol Metab 2003;88(10):4525-32. 
 
121. Basit A, Hakeem R, Hydrie MZI, Ahmadani MY & Masood Q, Relation 
between family history, obesity and risk for diabetes & heart disease in 
Pakistani children Pak J Med Sci 2004, 20(4) 296-302. 
 
122. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model 
assessment: insulin resistance and b-cell function from fasting plasma 
glucose and insulin concentration. Diabetologia 1985; 28: 412–9. 
 
123. Levy JC, Matthews DR, Herman MP. Correct homeostasis model 
assessment      (HOMA) evaluation uses the computer program. Diabetes 
Care 1998; 21: 2191–2. 
 
124. Alberti, Michal P Stern, International textbook of diabetes, 2nd edition 
12(255-256).1998. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices 
Informed Consent 
 
 
Diabetic Association of Pakistan and World Health Organization Collaborating Center 
 
Muhammad Zafar 
 
96
CONSENT FORM 
Title of Research Project:         
Prevalence of Type 2 Diabetes and Associated Risk Factors among Adults 25 Years 
and Above in Urban Karachi 
 
Explanation of Research Project: 
PURPOSE OF STUDY 
The doctors and health workers here are working with researchers at 
  
1. Diabetic Association of Pakistan and World Health Organization Collaborating 
Centre; 
2. Interactive Communications Research and Development Division; 
3. Baqai Institute of Diabetology and Endocrinology 
4. Lyari Community Development Project 
 
to find out about diabetes and heart disease in adults. Your household has been selected randomly from 
a list of all households in Lyari / North Nazimabad. The researchers undertaking this survey would like 
to ask you to participate in this study. 
PROCEDURES 
If you agree we will ask you questions about  
1. your household and members of your household.  
2. your lifestyle (e.g. diet, exercise) and existing conditions related to diabetes and heart 
disease.  
 
We will take measurements of your height, weight, hips, waist, abdomen and blood pressure. 
The doctors would like to take a blood sample from you after you have fasted overnight to test 
for high levels of glucose, lipids and liver enzymes.  You will be informed of the glucose test 
results within 3 days but the results of some of the other tests will take longer.  
 
Do you agree to provide blood to test for glucose, lipids and liver enzymes: Yes __; No ___  
 
We would also like to store your blood sample to test for infections that might cause liver 
disease. The blood sample may be stored for up to 10 years.  The samples will be stored in a 
manner that will not identify you by name. The results from these future tests may not be 
available to you.  
 
Do you agree to let the blood sample be stored for up to 10 years for future research?  Yes 
____; No _____ 
 
The data from the study will be kept in an office in Karachi. Information about your child will 
be available only to people working on the study. We will keep the study information private 
to the extent possible by the laws of Pakistan. People responsible for making sure that the 
research is done properly may review your study records.  This might include people from the 
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Baqai Institute of Diabetology and Endocrinology and the Lyari Community Development 
Project.  
RISKS AND DISCOMFORTS 
If blood is taken the needle stick may cause some discomfort and bruising.  
BENEFITS 
The test results will be given to you.  Any doctors that you visit will benefit by finding out if 
you have diabetes or risk factors for diabetes and heart disease. This information will also 
help researchers and doctors in understanding the causes of diabetes and heart disease in 
adults in Lyari / North Nazimabad and to plan programs to prevent these diseases. If you do 
not have diabetes or risk factors for diabetes and heart disease, you will be able to continue 
your lifestyle knowing that you are at low risk. You will not receive any payment for 
participating in this study.  
 
You are not forced to be in this study. You may leave the study at any time.  If you decide not 
to be in the study, your care or relations with your doctors will not be changed in any way. 
You should ask the project coordinator any questions you may have about this study. You 
may ask him/her questions in the future if you do not understand anything. The researchers 
will tell you any new information that they may find out while you are in this study. 
 
If you think being in the study has hurt you, you have not been treated fairly you can call the 
Principal Investigator Dr. A Samad Shera at 661-6890 (Karachi). You can also call the Project 
Coordinator Dr. Aamir Khan at 439-6254 (Karachi). You can also call Dr. Abdul Basit at the 
Baqai Institute of Diabetology and Endocrinology at 661-7234 (Karachi) and Mr. Abdur 
Rahim Moosvi at the Lyari Community Development Project at 752-1687 (Karachi). 
 
If you agree to participate in this study please sing your name below. 
 
____________________________________________ 
Signature  
____________________________________ 
Witness to Consent Procedures* 
____________________________________________ 
Signature of Investigator 
 
____________________________________________ 
Date 
*Optional unless subject is illiterate, or unable to sign 
 
Note: Signed copies of this form must be a) retained in file by the Principal  
Investigator, b) given to the participant and c) put in the patient’s medical record (when applicable). 
 
 
 
 
 
 
 
 
 
 
Void One Year From Above Date 
No. ___________________________ 
Approved From ___________ to ___________ 
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Structured Interview Questionnaire (11 Pages) 
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Approval of Local Ethics Committee 
REVIEW AND APPROVAL OF PREVALENCE OF DIABETES AND ASSOCIATED 
RISK FACTORS AMONG ADULTS 25 YEARS AND ABOVE IN URBAN KARACHI  
By INSTITUTIONAL REVIEW BOARD 
A: INFORMATION 
 
Name and Address of Ethical Review Board: 
Institutional Review Board 
Baqai Institute of Diabetology and Endocrinology, III- B, 3/17, Nazimabad No. 3, Karachi- 74600 
 
Study Title: 
‘Prevalence of Diabetes and Associated Risk Factors among Adults 25 Years and Above in Urban Karachi’. 
 
Name and Address of the Principal Investigator: 
Prof A. Samad Shera  TI, SI, FRCP  
Honorary President IDF 
Director WHO Collaborating Centre 
Secretary General DAP  
5-E/3, Nazimabad, Karachi-74600 
Ph: + 92-21-6616890  Email: dapkhi@cyber.net.pk  
 
B: REVIEW 
 
The following items have been reviewed in connection with the above study to be conducted by the above 
investigator: 
  Protocol      
  Informed Consent Document   
  Questionnaire / Patient Information Sheet   
 
 Conditionally approved (specify required modification here or in accompanying letter): 
1. Final Questionnaire to be submitted in local language ‘Urdu’ before start of study. 
2. Consent Form in Local Language ‘Urdu’.  
Date of IRB Approval: June 9, 2004     
          Dr. Shakil Baig 
          Chairman, 
                       Institutional Review Board 
INSTITUTIONAL REVIEW BOARD MEMBERS 
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